var title_f12_38_12896="Loading the wire I";
var content_f12_38_12896=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F52590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F52590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Loading the wire technique for precut sphincterotomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 389px; height: 258px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cartoon depicting the \"loading the wire\" technique for creating a biliary sphincterotomy (see text for details).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Douglas A Howell, MD and David J Desilets, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_38_12896=[""].join("\n");
var outline_f12_38_12896=null;
var title_f12_38_12897="Incontinentia pigmenti";
var content_f12_38_12897=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F58769&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F58769&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Incontinentia pigmenti",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erythematous papules, vesicles, and crusts are present in linear streaks&nbsp;on the leg of this female&nbsp;infant.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_38_12897=[""].join("\n");
var outline_f12_38_12897=null;
var title_f12_38_12898="Patient information: Stevens-Johnson syndrome (The Basics)";
var content_f12_38_12898=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?0/30/483\">",
"         Patient information: Dealing with side effects from medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/43/37554\">",
"         Patient information: Medicine brand and generic names (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Stevens-Johnson syndrome (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H186875862\">",
"      <span class=\"h1\">",
"       What is Stevens-Johnson syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Stevens-Johnson syndrome, also called &ldquo;SJS,&rdquo; is a rare but very serious problem that affects the skin. It causes the skin to turn red or purple and to peel away from the body. It can affect the skin on the outside of the body, as well as the pink, moist skin that lines your mouth, nose, eyes, and other body parts.",
"     </p>",
"     <p>",
"      A related skin problem, called &ldquo;toxic epidermal necrolysis,&rdquo; or &ldquo;TEN,&rdquo; is very similar to SJS but is more severe. Both conditions are treated in very much the same way.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H186875877\">",
"      <span class=\"h1\">",
"       What are the symptoms of SJS?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most important symptoms of SJS are those that affect the skin. In the first few days, before the skin symptoms show up, SJS causes:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Fever (often higher than 102&deg;F or 39&deg;C)",
"       </li>",
"       <li>",
"        Flu-like illness",
"       </li>",
"       <li>",
"        Itching or burning eyes",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Later, the symptoms of SJS include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Patches of red and painful skin",
"       </li>",
"       <li>",
"        Bruises that can have a blister on top",
"       </li>",
"       <li>",
"        Blisters or peeling skin on the chest, face, palms of hands, or soles of feet",
"       </li>",
"       <li>",
"        Sores, swelling, and crusting on the pink, moist skin lining the mouth, eyes, vagina, penis, lungs, and other areas &ndash; This can lead to:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        The eyes getting red and watering",
"       </li>",
"       <li>",
"        Parts of the eye sticking to each other",
"       </li>",
"       <li>",
"        Pain with urination or trouble urinating",
"       </li>",
"       <li>",
"        Trouble breathing, fluid build-up in the lungs, or lung infections",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H186875892\">",
"      <span class=\"h1\">",
"       What causes SJS?",
"      </span>",
"      &nbsp;&mdash;&nbsp;SJS is a rare side effect of a medicine, but it can also happen to people who have an infection, such as HIV. There are many medicines that can cause SJS. The chance that 1 of these medicines will cause SJS is highest during the first 8 to 10 weeks of taking it. Some of the most common examples of medicines that can cause SJS include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicines used to treat gout, especially:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?2/14/2277?source=see_link\">",
"         Allopurinol",
"        </a>",
"        (brand names: Aloprim, Zyloprim)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Certain antibiotics, especially:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?23/2/23589?source=see_link\">",
"         Trimethoprim-sulfamethoxazole",
"        </a>",
"        and other &ldquo;sulfa&rdquo; drugs (brand names: Bactrim, Septra)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicines used to prevent seizures, called &ldquo;anti-epileptics,&rdquo; including:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?13/8/13446?source=see_link\">",
"         Carbamazepine",
"        </a>",
"        (sample brand names: Tegretol, Carbatrol)",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?7/49/7958?source=see_link\">",
"         Phenytoin",
"        </a>",
"        (brand names: Dilantin, Phenytek)",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?40/40/41605?source=see_link\">",
"         Lamotrigine",
"        </a>",
"        (brand name: Lamictal)",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?7/59/8117?source=see_link\">",
"         Phenobarbital",
"        </a>",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicines used to treat pain, including medicines called &ldquo;non-steroidal anti-inflammatory agents,&rdquo; or &ldquo;NSAIDs,&rdquo; especially:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?25/50/26405?source=see_link\">",
"         Meloxicam",
"        </a>",
"        (brand name: Mobic)",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?18/0/18437?source=see_link\">",
"         Piroxicam",
"        </a>",
"        (brand name: Feldene)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H186875907\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, if you develop symptoms of SJS, go to the emergency room right away or call 9-1-1 for an ambulance.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H186875922\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. Your doctor will probably be able to tell what is wrong by talking to you and doing an exam. Still, he or she might order tests to make sure something else is not causing your symptoms. For instance, the doctor might take a sample of skin (called a biopsy) and send it the lab. He or she might also order a blood test and other tests to check for signs of infection.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H186875937\">",
"      <span class=\"h1\">",
"       How is SJS treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment happens in the hospital and usually lasts 2 to 4 weeks. There you will see a team of different types of doctors, nurses, and other professionals. Some people with SJS are treated in burn centers.",
"     </p>",
"     <p>",
"      To treat SJS, your treatment team will:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Stop the medicine that caused SJS (if it was caused by a medicine)",
"       </li>",
"       <li>",
"        Try to keep your skin clean and as healthy as possible &ndash; This might involve scrubbing your skin, keeping it moist, adding dressings, or doing other things.",
"       </li>",
"       <li>",
"        Check you for signs of infection &ndash; This is very important because people SJS can develop serious infections.",
"       </li>",
"       <li>",
"        Give you antibiotics to treat infection",
"       </li>",
"       <li>",
"        Give you medicines to reduce inflammation, such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?27/36/28230?source=see_link\">",
"         prednisone",
"        </a>",
"        or a medicine called IVIG",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H186875952\">",
"      <span class=\"h1\">",
"       What happens after I have had SJS?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have had SJS, you must be very careful to",
"      <strong>",
"       never",
"      </strong>",
"      take the medicine that caused it again. If you take the same medicine again, it could kill you. You should wear a medic alert bracelet or necklace at all times that lists the medicine or medicines you must avoid and why. If you can&rsquo;t wear a bracelet or necklace, you should carry a document called an &ldquo;allergy passport&rdquo; at all times. You should also learn all the names of the medicines you should avoid. Medicines often go by more than 1 name, so you might have to learn a few. Your doctor or nurse should give you a list of all the names you should know.",
"     </p>",
"     <p>",
"      If you had SJS caused by a medicine, your doctor might suggest that your family members take a blood test to find out if they could be at risk of getting SJS with the same medicine. That way they can also be careful not to take medicines that can cause SJS.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H186875967\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/30/483?source=see_link\">",
"       Patient information: Dealing with side effects from medicines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/43/37554?source=see_link\">",
"       Patient information: Medicine brand and generic names (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?12/38/12898?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 87114 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-BFBE39938F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_38_12898=[""].join("\n");
var outline_f12_38_12898=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H186875862\">",
"      What is Stevens-Johnson syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H186875877\">",
"      What are the symptoms of SJS?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H186875892\">",
"      What causes SJS?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H186875907\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H186875922\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H186875937\">",
"      How is SJS treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H186875952\">",
"      What happens after I have had SJS?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H186875967\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/30/483?source=related_link\">",
"      Patient information: Dealing with side effects from medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/43/37554?source=related_link\">",
"      Patient information: Medicine brand and generic names (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_38_12899="CW doppler of MR V wave cut";
var content_f12_38_12899=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F51062&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F51062&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Continuous wave Doppler of the mitral regurgitation jet demonstrating the 'V-wave cutoff' configuration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 425px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This configuration is characterized by an abrupt deceleration from peak velocity and reflects the abrupt drop in gradient between ventricle and atrium resulting from regurgitant V-wave.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Xiushui Ren, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_38_12899=[""].join("\n");
var outline_f12_38_12899=null;
var title_f12_38_12900="Crotamiton: Patient drug information";
var content_f12_38_12900=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Crotamiton: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/45/13011?source=see_link\">",
"     see \"Crotamiton: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/5/4179?source=see_link\">",
"     see \"Crotamiton: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F155020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Eurax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14959735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Eurax Cream",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat scabies.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691918",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat itching.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701868",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to crotamiton or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696732",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on irritated skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696645",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid touching to the face, eyes, and mouth.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698468",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check for live mites.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698969",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Live mites found after a second round of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705883",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Scabies:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696244",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash clothing, bedding, and bath towels.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695612",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Scrub away any loose scales on body during bathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake lotion well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694443",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the skin from the neck to the toes. Put in the skin folds, creases, and spaces between the fingers and toes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a second dose after 24 hours.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695737",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a bath 48 hours after putting on the second dose.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695586",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Repeat after 7 to 10 days if live mites are found.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705882",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Itching:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12343 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-201.211.0.116-8A73E14F39-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_38_12900=[""].join("\n");
var outline_f12_38_12900=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155020\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14959735\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030480\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030479\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030484\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030485\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030487\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030482\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030483\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030488\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030489\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/45/13011?source=related_link\">",
"      Crotamiton: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/5/4179?source=related_link\">",
"      Crotamiton: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_38_12901="Neomycin, polymyxin B, and hydrocortisone: Patient drug information";
var content_f12_38_12901=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Neomycin, polymyxin B, and hydrocortisone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/42/24228?source=see_link\">",
"     see \"Neomycin, polymyxin B, and hydrocortisone: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/18/38179?source=see_link\">",
"     see \"Neomycin, polymyxin B, and hydrocortisone: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F200652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cortisporin&reg;;",
"     </li>",
"     <li>",
"      Cortomycin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F200653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cortimyxin&reg;;",
"     </li>",
"     <li>",
"      Cortisporin&reg; Otic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691827",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat ear infections.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691501",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat eye infections.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692076",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702590",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to neomycin, polymyxin B, hydrocortisone, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698033",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Ear irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blurred eyesight. Use care when driving or doing other tasks that call for clear eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697926",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bright lights may bother you. Wear sunglasses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705551",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Eye:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 15 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705375",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Ear:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the ear only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695632",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake suspension well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695296",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Lie on your side with problem ear up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705870",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pull the outer ear outward and upward.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695239",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put drops in ear without touching dropper to ear. Stay on side for 2 minutes or put cotton plug in ear.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11806 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-122.72.76.133-33CB703E27-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_38_12901=[""].join("\n");
var outline_f12_38_12901=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200652\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200653\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013974\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013973\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013978\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013979\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013981\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013976\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013977\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013982\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013983\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/42/24228?source=related_link\">",
"      Neomycin, polymyxin B, and hydrocortisone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/18/38179?source=related_link\">",
"      Neomycin, polymyxin B, and hydrocortisone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_38_12902="Sinusoidal FHR pattern";
var content_f12_38_12902=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61189&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61189&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 555px\">",
"   <div class=\"ttl\">",
"    Sinusoidal FHR pattern",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 535px; height: 235px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sinusoidal heart rate pattern in a patient presenting with spontaneous fetomaternal hemorrhage near term. The patient reported decreased fetal movement.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_38_12902=[""].join("\n");
var outline_f12_38_12902=null;
var title_f12_38_12903="Eprosartan and hydrochlorothiazide: Drug information";
var content_f12_38_12903=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Eprosartan and hydrochlorothiazide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?32/6/32869?source=see_link\">",
"    see \"Eprosartan and hydrochlorothiazide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F165990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Teveten&reg; HCT",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F165991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Teveten&reg; HCT;",
"     </li>",
"     <li>",
"      Teveten&reg; Plus",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F166008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Angiotensin II Receptor Blocker;",
"     </li>",
"     <li>",
"      Diuretic, Thiazide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F165994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypertension: Oral: Dose is individualized (combination substituted for individual components)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Usual recommended dose: Eprosartan 600 mg/hydrochlorothiazide 12.5 mg once daily (maximum dose: Eprosartan 600 mg/hydrochlorothiazide 25 mg once daily)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F165995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F165996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Moderate-to-severe impairment: Initial dose adjustments are not necessary per  manufacturer; however carefully monitor patient. Do not exceed a maximum dose of eprosartan 600 mg daily. Hydrochlorothiazide is ineffective in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F165997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Initial dose adjustments not recommended by manufacturer; carefully monitor patient.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F165977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     600 mg/12.5 mg: Eprosartan 600 mg and hydrochlorothiazide 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     600 mg/25 mg: Eprosartan 600 mg and hydrochlorothiazide 25 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F165966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9518024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F165978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension (not indicated for initial treatment)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F166006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Percentages reported with combination product; other reactions have been reported (see individual agents for additional information).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (4%), headache (3%), fatigue (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Neutrophil count decreased (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: BUN increased (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anemia, hyperkalemia (0.9%), hypotension, liver enzyme (ALT) increased, myalgia, orthostasis, thrombocytopenia, upper respiratory tract infection; rhabdomyolysis has been reported (rarely) with angiotensin-receptor antagonists",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F165981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to eprosartan, hydrochlorothiazide, or any component of the formulation; sulfonamide-derived drugs; concomitant use with aliskiren in patients with diabetes mellitus; anuria",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F3013501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte disturbances: Hyperkalemia may occur with angiotensin II receptor antagonists; risk factors include renal dysfunction, diabetes mellitus, and concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts. Use cautiously, if at all, with these agents and monitor potassium closely. Thiazide diuretics may cause hypokalemia, hypochloremic alkalosis, hypomagnesemia, and hyponatremia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Hypersensitivity reactions may occur with hydrochlorothiazide. Risk is increased in patients with a history of allergy or bronchial asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: Symptomatic hypotension may occur upon initiation in patients who are salt- or volume-depleted (eg, those treated with high-dose diuretics); correct volume depletion prior to administration. This transient hypotensive response is not a contraindication to further treatment with eprosartan.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: Hydrochlorothiazide may cause acute transient myopia and acute angle-closure glaucoma, typically occurring within hours to weeks following initiation; discontinue therapy immediately in patients with acute decreases in visual acuity or ocular pain. Risk factors may include a history of sulfonamide or penicillin allergy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: Photosensitization may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal function deterioration: May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfa allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe. Discontinue if signs of hypersensitivity are noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aortic/mitral stenosis: Use with caution in patients with significant aortic/mitral stenosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use hydrochlorothiazide with caution in patients with prediabetes or diabetes mellitus; may see a change in glucose control.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gout: In certain patients with a history of gout, a familial predisposition to gout, or chronic renal failure, gout can be precipitated by hydrochlorothiazide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use caution in patients with moderate hepatic impairment; in cirrhosis, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypercalcemia: Thiazide diuretics may decrease renal calcium excretion; consider avoiding use in patients with hypercalcemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypercholesterolemia: Use with caution in patients with moderate or high cholesterol concentrations; increased cholesterol and triglyceride levels have been reported with thiazides.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Parathyroid disease: Thiazide diuretics reduce calcium excretion; pathologic changes in the parathyroid glands with hypercalcemia and hypophosphatemia have been observed with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal artery stenosis: Use eprosartan with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use eprosartan with caution with pre-existing renal insufficiency and severe renal impairment. Avoid hydrochlorothiazide in severe renal disease (ineffective); may precipitate azotemia; discontinue or consider withholding if renal impairment occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic lupus erythematosus (SLE): Hydrochlorothiazide can cause SLE exacerbation or activation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angiotensin-converting enzyme (ACE) inhibitors and renin inhibitors: Concomitant use of an ACE-inhibitor or renin inhibitor (eg, aliskiren) is associated with an increased risk of hypotension, hyperkalemia, and renal dysfunction. Concomitant use with aliskiren should be avoided in patients with GFR &lt;60 mL/minute and is contraindicated in patients with diabetes mellitus (regardless of GFR).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F165971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Thiazide Diuretics may enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the hypotensive effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the nephrotoxic effect of Angiotensin II Receptor Blockers. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically, Thiazide Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benazepril: Hydrochlorothiazide may enhance the hypotensive effect of Benazepril. Hydrochlorothiazide may enhance the nephrotoxic effect of Benazepril. Benazepril may decrease the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Thiazide Diuretics. The diuretic response is likewise decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: Thiazide Diuretics may decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Canagliflozin may enhance the hypotensive effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Thiazide Diuretics may enhance the QTc-prolonging effect of Dofetilide. Thiazide Diuretics may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Licorice: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Thiazide Diuretics may decrease the excretion of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Angiotensin II Receptor Blockers may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an angiotensin II receptor antagonist.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Thiazide Diuretics may enhance the hypercalcemic effect of Multivitamins/Minerals (with ADEK, Folate, Iron).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: Thiazide Diuretics may enhance the adverse/toxic effect of OXcarbazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Angiotensin II Receptor Blockers may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ARBs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Thiazide Diuretics may enhance the hypokalemic effect of Topiramate. Thiazide Diuretics may increase the serum concentration of Topiramate.  Management: Monitor for increased topiramate levels/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: Thiazide Diuretics may enhance the hypercalcemic effect of Toremifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valsartan: Hydrochlorothiazide may enhance the hypotensive effect of Valsartan. Valsartan may increase the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Thiazide Diuretics may enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F165973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F165983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     Also see individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F166000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F165984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion of eprosartan in breast milk is not known and use during nursing is not recommended; hydrochlorothiazide is excreted in breast milk",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F165985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F165982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Teveten HCT Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600-12.5 mg (100): $488.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600-25 mg (100): $488.15",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F165975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure; serum electrolytes, BUN, creatinine",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F165986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Co Teveten (FR);",
"     </li>",
"     <li>",
"      Futuran Plus (ES);",
"     </li>",
"     <li>",
"      Teveten Comp (DK, FI, NO, SE);",
"     </li>",
"     <li>",
"      Teveten Plus (AT, AU, BE, BG, CH, DE, EE, GR, HK, IE, KP, NL, PH, PT, RU);",
"     </li>",
"     <li>",
"      Teveten Plus H (CZ);",
"     </li>",
"     <li>",
"      Tevetens Plus (ES)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F165968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Hydrochlorothiazide",
"     </b>",
"     inhibits sodium reabsorption in the distal tubules causing increased excretion of sodium and water as well as potassium and hydrogen ions.",
"     <b>",
"      Eprosartan",
"     </b>",
"     blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F165980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl ):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/38/12903/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, &ldquo;ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration With the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2007, 50(7):e1-e157.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/38/12903/abstract-text/17692738/pubmed\" id=\"17692738\" target=\"_blank\">",
"        17692738",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Hand M, Armstrong PW, et al, &ldquo;2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 51(2):210-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/38/12903/abstract-text/18191746/pubmed\" id=\"18191746\" target=\"_blank\">",
"        18191746",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/38/12903/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohn JN and Tognoni G, &ldquo;Valsartan Heart Failure Trial Investigators. A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(23):1667-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/38/12903/abstract-text/11759645/pubmed\" id=\"11759645\" target=\"_blank\">",
"        11759645",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dahlof B, Devereux RB, Kjeldsen SE, et al, &ldquo;Cardiovascular Morbidity and Mortality in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): A Randomised Trial Against Atenolol,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2002, 359(9311):995-1003.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/38/12903/abstract-text/11937178/pubmed\" id=\"11937178\" target=\"_blank\">",
"        11937178",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dickstein K, Kjekshus J, et al, &ldquo;Effects of Losartan and Captopril on Mortality and Morbidity in High-Risk Patients After Acute Myocardial Infarction: The OPTIMAAL Randomised Trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2002, 360(9335):752-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/38/12903/abstract-text/12241832/pubmed\" id=\"12241832\" target=\"_blank\">",
"        12241832",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Epstein BJ and Gums JG, &ldquo;Angiotensin Receptor Blockers Versus ACE Inhibitors: Prevention of Death and Myocardial Infarction in High-Risk Populations,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2005, 39(3):470-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/38/12903/abstract-text/15701766/pubmed\" id=\"15701766\" target=\"_blank\">",
"        15701766",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Granger CB, McMurray JJ, Yusuf S, et al, &ldquo;Effects of Candesartan in Patients With Chronic Heart Failure and Reduced Left-Ventricular Systolic Function Intolerant to Angiotensin-Converting-Enzyme Inhibitors: The CHARM-Alternative Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 362(9386):772-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/38/12903/abstract-text/13678870/pubmed\" id=\"13678870\" target=\"_blank\">",
"        13678870",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Kidney Disease Outcome Quality Initiative,&rdquo;",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2002, 39(2 Suppl 2):1-246. Available at file://www.kidney.org/professionals/KDOQI/guidelines_ckd/toc.htm",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McMurray JJ, Ostergren J, Swedberg K, et al, &ldquo;Effects of Candesartan in Patients With Chronic Heart Failure and Reduced Left-Ventricular Systolic Function Taking Angiotensin-Converting-Enzyme Inhibitors: The CHARM-Added Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 362(9386):767-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/38/12903/abstract-text/13678869/pubmed\" id=\"13678869\" target=\"_blank\">",
"        13678869",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pfeffer MA, McMurray JJ, Velazquez EJ, et al, &ldquo;Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 350(2):203.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pitt B, Poole-Wilson PA, Segal R, et al, &ldquo;Effect of Losartan Compared With Captopril on Mortality in Patients With Symptomatic Heart Failure: Randomised Trial - The Losartan Heart Failure Survival Study ELITE II,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      ,  2000, 355(9215):1582-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/38/12903/abstract-text/10821361/pubmed\" id=\"10821361\" target=\"_blank\">",
"        10821361",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sipahi I, Debanne SM, Rowland DY, et al, &ldquo;Angiotensin-Receptor Blockade and Risk of Cancer: Meta-Analysis of Randomised Controlled Trials,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2010, 11(7):627-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/38/12903/abstract-text/20542468/pubmed\" id=\"20542468\" target=\"_blank\">",
"        20542468",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8636 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-B4DFEB0FC9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_38_12903=[""].join("\n");
var outline_f12_38_12903=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708745\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165990\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165991\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166008\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165994\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165995\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165996\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165997\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165977\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165966\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9518024\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165978\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166006\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165981\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3013501\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299276\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165971\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165973\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165983\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166000\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165984\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165985\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165982\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165975\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165986\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165968\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165980\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8636\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8636|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/6/32869?source=related_link\">",
"      Eprosartan and hydrochlorothiazide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_38_12904="Smoking cessation counseling strategies in primary care";
var content_f12_38_12904=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Smoking cessation counseling strategies in primary care",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/38/12904/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/38/12904/contributors\">",
"     Joyce A Sackey, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/38/12904/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/38/12904/contributors\">",
"     Robert H Fletcher, MD, MSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/38/12904/contributors\">",
"     James K Stoller, MS, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/38/12904/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/38/12904/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/38/12904/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary care clinicians are in a strategic position to help their patients quit smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12904/abstract/1\">",
"     1",
"    </a>",
"    ]. It has been estimated that at least 70 percent of smokers see a physician each year [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12904/abstract/2\">",
"     2",
"    </a>",
"    ]; 70 percent also report a desire to quit and make at least one serious attempt to do so [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12904/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, smokers cite a physician's advice to quit as an important motivating factor for attempting to quit; brief advice from a physician leads to a spontaneous quit rate of 2 to 4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12904/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. The National Cancer Institute estimates that if 100,000 physicians were to assist 10 percent of their patients who smoke to quit each year, the number of smokers in the United States would decrease at a rate of 2 million people annually.",
"   </p>",
"   <p>",
"    The behavioral approach to smoking cessation will be reviewed here. An overview of smoking cessation management, and pharmacologic therapy for smoking cessation, are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link\">",
"     \"Overview of smoking cessation management in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/13/17626?source=see_link\">",
"     \"Pharmacotherapy for smoking cessation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the benefits of smoking cessation, clinicians are not adequately screening and treating patients who smoke. One study, for example, found that only 50 percent of smokers seeing a primary care physician in the past year were asked about their smoking or urged to quit [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12904/abstract/5\">",
"     5",
"    </a>",
"    ]. An even smaller proportion was counseled to quit. Some of the barriers to clinician intervention include time constraints, a perception that the clinician lacks the skills necessary to be effective in this role, and low expectation of successfully getting smokers to quit.",
"   </p>",
"   <p>",
"    Several developments in the treatment of smoking may change the role of the clinician in confronting tobacco use among their patients. Practice guidelines calling for the treatment of all tobacco users have been released by the Agency for Health Care Policy and Research (AHCPR) and the United States Preventive Health Service; these were based on an exhaustive systematic review and analysis of the scientific literature from 1975 to 1999, and were published in the year 2000 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12904/abstract/6\">",
"     6",
"    </a>",
"    ]. The American Psychiatric Association (APA) also released nearly identical guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12904/abstract/7\">",
"     7",
"    </a>",
"    ]. Clinicians now have available a clearly defined standard of screening and intervention to use with their patients.",
"   </p>",
"   <p>",
"    The field of smoking cessation treatment itself also is rapidly expanding. Randomized controlled trials of commonly used smoking cessation techniques, including individual, group, and telephone counseling, have demonstrated success in helping smokers quit and maintaining long-term abstinence [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12904/abstract/6\">",
"     6",
"    </a>",
"    ]. In addition, rapid expansion in pharmacotherapy has resulted in multiple drug agents and systems of delivery directed at treating the biologic basis of tobacco addiction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ASSESSMENT OF USE AND EXPOSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Agency for Health Care Policy and Research (AHCPR) guidelines recommend that the tobacco use status of every patient treated in a healthcare setting be assessed and documented at every visit (",
"    <a class=\"graphic graphic_table graphicRef74402 \" href=\"UTD.htm?40/33/41500\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12904/abstract/6\">",
"     6",
"    </a>",
"    ]. This practice has been shown to increase the likelihood of smoking-related discussions between patients and physicians and to increase smoking cessation rates [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12904/abstract/1,8,9\">",
"     1,8,9",
"    </a>",
"    ]. Most of the following discussion refers to cigarette smoking, although smokeless tobacco use also is associated with significant health risk and should not be overlooked. Cigar smoking (which appears to be on the rise) and the use of tobacco pipes also should be documented.",
"   </p>",
"   <p>",
"    Exposure to secondhand smoke should be assessed in every nonsmoking patient. There is growing evidence that secondhand smoke may confer similar, albeit lower health hazards. Nonsmokers should be queried about regular exposure to tobacco use at home and at work. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22505?source=see_link\">",
"     \"Secondhand smoke exposure: Effects in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ENHANCING THE MOTIVATION TO QUIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Every smoker should be asked if he or she is willing to quit. If the patient wants to attempt to quit, the clinician should guide the patient in selecting an appropriate treatment.",
"   </p>",
"   <p>",
"    It is important to understand the stages of motivation to change behavior in order to plan an effective intervention. The following stages of change have been described:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Precontemplation &mdash; The patient states",
"      <span class=\"nowrap\">",
"       he/she",
"      </span>",
"      is not ready to quit. The patient's motivation status should be documented and monitored at every subsequent visit.",
"     </li>",
"     <li>",
"      Contemplation &mdash; The patient is considering smoking cessation at some point in the future. The patient at this stage should be encouraged to select a specific quit date and to engage in preparation toward that date.",
"     </li>",
"     <li>",
"      Determination &mdash; The patient is actively considering cessation soon and is engaging in some quit-oriented behavior. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Treatment strategies'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Action &mdash; The patient is actively involved in a quit attempt and has quit smoking within the last six months.",
"     </li>",
"     <li>",
"      Maintenance &mdash; The patient has quit for at least six months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The importance of specific advice to quit smoking, regardless of the patient's motivational status, should be underscored. Every patient who smokes should be urged to quit in a clear, strong, and personalized manner. Not every patient counseled on smoking cessation will be prepared to consider quitting. Nevertheless, it is important that the patient's smoking and motivational status be ascertained at each encounter. In a systematic review of 20 studies conducted in primary care settings, brief (&le;5 minute) interventions that included advice to quit smoking resulted in 2 percent of all smokers quitting, compared with &lt;1 percent of those who received no advice [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12904/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is some evidence to suggest that the main therapeutic effect of physician advice is to promote motivation to quit in ambivalent smokers, rather than helping already motivated smokers to stop [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12904/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Smokers who are asked about tobacco use or are advised to quit smoking may be more satisfied with their care than patients who do not receive such advice, even if they are not ready to quit [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12904/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A randomized trial found that informing patients of their \"lung age\" as determined by spirometry (age of a healthy person with the same lung function) doubled quit rates at 12 months (14 versus 6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12904/abstract/13\">",
"     13",
"    </a>",
"    ]. The effect did not appear to be altered by whether the lung age was normal or abnormal. There is little evidence that other types of biomedical risk assessment increase smoking cessation rates compared to standard care [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12904/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The AHCPR has proposed the model of \"5 Rs\" in promoting motivation to quit smoking (",
"    <a class=\"graphic graphic_table graphicRef70628 \" href=\"UTD.htm?17/58/18349\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Relevance &mdash; Motivational information to a patient is more effective if it is relevant to a patient's circumstances (such as prior quitting experience, disease status, or health concerns).",
"     </li>",
"     <li>",
"      Risks &mdash; The acute and long-term risks of smoking should be stressed. It is most effective if smoking can be tied to the patient's current health or illnesses. For the healthy patient, environmental risks, such as exposing spouses and children to smoking and thereby increasing their risk of ill-health should be included. Smokers should also be made aware that children of smokers are more likely to smoke.",
"     </li>",
"     <li>",
"      Rewards &mdash; Encourage the patient to identify potential benefits of smoking (such as saving money, performing better in sports, improving the health of children and other household members, etc).",
"     </li>",
"     <li>",
"      Roadblocks &mdash; Ask the patient to identify barriers or impediments to quitting and note elements of treatment (problem solving, pharmacotherapy) that could address barriers.",
"     </li>",
"     <li>",
"      Repetition &mdash; Repeat the motivational intervention each time an unmotivated smoker visits the clinic setting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TREATMENT STRATEGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who are ready to quit smoking (eg, in the determination stage), an action plan should be devised (",
"    <a class=\"graphic graphic_table graphicRef74402 \" href=\"UTD.htm?40/33/41500\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef52690 \" href=\"UTD.htm?39/23/40316\">",
"     table 3",
"    </a>",
"    ). The first step in forming an action plan is to set a quit date. Ideally, this date should be within two weeks.",
"   </p>",
"   <p>",
"    Patients should also be encouraged to make the following preparations for quitting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inform family, friends, and coworkers of the plan to quit, and explicitly ask for support.",
"     </li>",
"     <li>",
"      Avoid smoking in the home, car, and other places where a lot of time is spent.",
"     </li>",
"     <li>",
"      Review prior quit attempts. What worked? What didn't work and may have contributed to relapse?",
"     </li>",
"     <li>",
"      Anticipate nicotine withdrawal symptoms, cues to smoking, and \"danger situations.\"",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Three elements of successful smoking cessation treatment strategies have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12904/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Social support",
"     </li>",
"     <li>",
"      Pharmacologic therapy",
"     </li>",
"     <li>",
"      Skills training or problem-solving techniques",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One or more of these elements should be included in a treatment plan. Ultimately, patient preference and beliefs should be the most important factors to consider in selecting a particular treatment modality.",
"   </p>",
"   <p>",
"    Evidence suggests there is growing motivation among patients to make a quit attempt, and increased acceptance of pharmacologic smoking cessation aides. A comparative effective study based at several primary care practices found that one in five smokers attending a routine primary care appointment was willing to make a serious quit attempt with the help of treatment that incorporated evidence-based counseling and some form of pharmacologic aide [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12904/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Self-help materials may help patients deal with some of the challenges that will arise. In addition, patients should be encouraged to use some sort of pharmacologic therapy, unless it is contraindicated [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12904/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is particularly important to screen for the presence of a psychiatric comorbidity. The American Psychiatric Association guideline specifically recommends screening for the presence of depression, schizophrenia, alcohol, and other chemical dependency [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12904/abstract/7\">",
"     7",
"    </a>",
"    ]. This recommendation is supported by the finding that smokers are more likely than nonsmokers to have symptoms of affective disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12904/abstract/17\">",
"     17",
"    </a>",
"    ]. Furthermore, people with a negative affect are more likely to start smoking, and less likely to be able to quit [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12904/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a dose-response relationship between the intensity of tobacco dependence counseling and its effectiveness in smoking cessation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12904/abstract/6\">",
"     6",
"    </a>",
"    ]. In general, counseling can be performed either in person or over the telephone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H125250936\">",
"    <span class=\"h3\">",
"     Clinician counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brief clinician follow-up contact is important for achieving smoking cessation and sustaining abstinence. The clinician should arrange for follow-up contact either in person or by telephone soon after the quit date. The following points should be a covered at this time:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Congratulate the patient for successfully quitting and encourage continued total abstinence (a single puff may lead to relapse).",
"     </li>",
"     <li>",
"      Discuss any problems that may have arisen as a result of smoking cessation (eg, depressed mood, weight gain, lack of support from friends and family, or prolonged withdrawal symptoms). Make concrete recommendations on how to deal with these issues.",
"     </li>",
"     <li>",
"      Consider extending or increasing pharmacotherapy if withdrawal symptoms persist.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These brief encounters (lasting five minutes or less) may be adequate for some patients. For others, more intensive psychological assessment and follow-up are necessary. A stepped-care approach has been proposed in which, throughout subsequent attempts to quit, smokers are offered a progressively more intensive therapy starting from self-help strategies to more intensive psychological intervention.",
"   </p>",
"   <p>",
"    Meta-analyses of randomized trials have found a strong dose-response relationship between the duration of counseling (both number of sessions and length of each session) and abstinence rates (",
"    <a class=\"graphic graphic_table graphicRef65033 \" href=\"UTD.htm?43/28/44491\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12904/abstract/19\">",
"     19",
"    </a>",
"    ]. Clinician counseling sessions &gt;10 minutes more than doubles the rate of abstinence compared to no counseling. Clinician counseling may consist of multiple visits, often weekly, starting before the quit date and continuing for one to two months after the quit date to optimally support a smoker through the quitting process. These programs are more effective than simple self-help interventions, in which smokers are provided with take-home print or audiovisual material to aid them in quitting on their own [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12904/abstract/20\">",
"     20",
"    </a>",
"    ]. Self-help interventions have proven to be ineffective when offered alone, although take-home materials can augment the efficacy of clinician counseling [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12904/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The US Public Health Service guideline developed a simple five-step algorithm called the 5 A's that operationalizes the elements of clinician counseling for office practice [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12904/abstract/19\">",
"     19",
"    </a>",
"    ]. This system encourages clinicians to",
"    <strong>",
"     ask",
"    </strong>",
"    patients about their smoking status,",
"    <strong>",
"     advise",
"    </strong>",
"    smokers to quit,",
"    <strong>",
"     assess",
"    </strong>",
"    their readiness to quit,",
"    <strong>",
"     assist",
"    </strong>",
"    them with their smoking cessation effort, and to",
"    <strong>",
"     arrange",
"    </strong>",
"    for follow-up visits or contact (",
"    <a class=\"graphic graphic_table graphicRef74402 \" href=\"UTD.htm?40/33/41500\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H149731929\">",
"    <span class=\"h3\">",
"     Telephone counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Telephone counseling can generally be provided in two ways: 1) proactive counseling, in which calls to smokers are initiated by a counselor according to a prearranged schedule and 2) reactive counseling, in which all calls to counselors are initiated by smokers.",
"   </p>",
"   <p>",
"    Proactive telephone counseling appears to be more effective than reactive counseling. In a meta-analysis of eight clinical trials, quit rates were higher for smokers randomly assigned to proactive counseling, compared to non-telephone based controls (OR 1.4, 95% CI 1.3-1.6) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12904/abstract/22\">",
"     22",
"    </a>",
"    ]. Three or more calls increased the chances of quitting. In contrast, data on reactive telephone counseling are mixed, with little to no benefit in quit rates among smokers receiving reactive counseling, compared to non-telephone based controls [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12904/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Smokers can access free, proactive telephone counseling throughout the US by calling a toll-free number (1-800-QUIT-NOW or 1-800-784-8669). Some states in the US have developed fax-referral programs to link clinician offices to the state telephone quitlines. Some quitlines distribute free nicotine replacement therapy to eligible quitline callers [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12904/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H125250234\">",
"    <span class=\"h3\">",
"     Mobile phone interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Behavioral interventions with cell phones are usually performed through text messages or mobile phone applications (apps).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Text messaging &mdash;",
"      <strong>",
"      </strong>",
"      Mobile phone text messaging allows patients to receive personalized smoking cessation support through a series of automated motivational messages. Messages suggest behavioral changes, provide positive feedback, and allow patients to request additional assistance as needed. Randomized trials have found that text messaging is effective for short- and long-term abstinence. In a meta-analysis including two randomized trials of 1905 smokers, text messaging increased self-reported tobacco cessation at four to six week follow-up, compared to control (RR 2.2, 95% CI 1.8-2.7) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/38/12904/abstract/25\">",
"       25",
"      </a>",
"      ]. In a subsequent trial of 5800 smokers, those randomly assigned to text messaging were more likely to stop smoking at six month follow-up compared to the control group (11 versus 5 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/38/12904/abstract/26\">",
"       26",
"      </a>",
"      ]. Abstinence was biochemically verified by cotinine sampling.",
"     </li>",
"     <li>",
"      Cell phone apps &mdash; Several types of behavioral interventions through mobile phones are being studied, including short video clips and cognitive behavioral tips to quit smoking; however, high-quality data to support mobile phone apps are lacking [",
"      <a class=\"abstract\" href=\"UTD.htm?12/38/12904/abstract/25\">",
"       25",
"      </a>",
"      ]. A review of the 47 iPhone smoking cessation apps available in 2009 found low adherence to the US Preventive Health Service clinical practice guidelines [",
"      <a class=\"abstract\" href=\"UTD.htm?12/38/12904/abstract/27\">",
"       27",
"      </a>",
"      ]. More studies are needed to test the efficacy of mobile phone apps and optimize their ability to help smokers quit.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H125250241\">",
"    <span class=\"h3\">",
"     Computer-based interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various web- and other computer-based programs have been developed to promote smoking cessation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12904/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. A meta-analysis of 22 randomized trials in 29,549 smokers found that use of such programs increased abstinence rates by approximately 45 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12904/abstract/28\">",
"     28",
"    </a>",
"    ]. The absolute increase in abstinence at 12 months was small (9.9 versus 5.7 percent). Interventions included both web- and home-based programs with educational modules, counseling,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    feedback. Another meta-analysis suggested that web-based interventions that were interactive or tailored to specific populations were more effective for smoking cessation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12904/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H125250248\">",
"    <span class=\"h3\">",
"     Group therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Group therapy allows smokers to learn behavioral techniques among their peers, with the intent of providing mutual support among group members [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12904/abstract/30\">",
"     30",
"    </a>",
"    ]. Group therapy is nearly twice as efficacious as self-help programs [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12904/abstract/30\">",
"     30",
"    </a>",
"    ]. One year quit rates for persons who complete such programs are approximately 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12904/abstract/19,31,32\">",
"     19,31,32",
"    </a>",
"    ]. Despite the efficacy of group therapy, only a minority of smokers are willing to attend them, citing the inconvenience.",
"   </p>",
"   <p>",
"    Group sessions typically include short didactic presentations about the quitting process, group interactions, exercises on self-monitoring of one's smoking habit, some form of tapering method leading to a quit date, development of coping skills, and suggestions among members for relapse prevention. Group therapy allows patients to learn behavioral techniques from several participant perspectives while mutually supporting others attempting to quit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Problem solving/skills training",
"    </span>",
"    &nbsp;&mdash;&nbsp;The smoker anticipating quitting should be encouraged to identify situations or activities that may increase the risk of smoking or relapse. Examples include having smokers within the household or at the workplace, getting into stressful situations, and alcohol use.",
"   </p>",
"   <p>",
"    Once the \"danger situations\" have been identified, coping skills should be explored. The nature and time course of withdrawal should be described. Learning strategies (cognitive and behavioral) that will reduce negative moods can be helpful.",
"   </p>",
"   <p>",
"    Strategies to enhance coping may include making lifestyle changes to reduce stress and improve quality of life (eg, starting an exercise program, learning relaxation techniques). In one randomized trial of 281 women smokers, vigorous exercise, used in conjunction with a cognitive-behavioral smoking cessation program, enhanced short and long-term (up to one year) abstinence, and delayed weight gain following smoking cessation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12904/abstract/33\">",
"     33",
"    </a>",
"    ]. Further investigation is required to clarify the potential role of exercise programs in promoting smoking cessation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12904/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The smoker should be encouraged to explore how to minimize the time spent in the company of smokers. When other smokers are in the home, the recent ex-smoker could consider negotiating with household members not to smoke within the home or car.",
"   </p>",
"   <p>",
"    The key to successful quitting is to equip the smoker with as much information as possible about what to expect during quit attempts. Supplementing information discussed during visits and on the telephone with self-help materials can serve both as a reinforcer and a time saving resource for the clinician [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12904/abstract/35\">",
"     35",
"    </a>",
"    ]. These materials include pamphlets or booklets and videos or audio tapes on smoking cessation, a hotline or help line, the internet, and support groups. Several medical centers now have patient resources or learning centers in which patients can access additional self-help materials. Web site resources include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"external\" href=\"file://www.lungusa.org/\">",
"       www.lungusa.org",
"      </a>",
"      &mdash; The web site for the American Lung Association, sponsor of the American Smoke-out Day, includes an online guide for smoking cessation",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.cancer.gov/cancertopics/tobacco\">",
"       www.cancer.gov/cancertopics/tobacco",
"      </a>",
"      &mdash; The National Cancer Institute web site contains information on smoking cessation in English and Spanish, as well as general information on the health effects of tobacco",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.quitnet.com/\">",
"       www.quitnet.com",
"      </a>",
"      &mdash; An excellent, comprehensive resource for patients",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.ahrq.gov/consumer/index.html\">",
"       www.ahrq.gov/consumer/index.html#smoking",
"      </a>",
"      &mdash; A good source for patient pamphlets on smoking cessation",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pharmacologic therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of effective pharmacologic therapies for smoking cessation. In the absence of contraindications patients should be encouraged to use one or more of these therapies in combination with behavioral approaches. The efficacy of pharmacologic therapies alone and in combination with behavioral approaches is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/13/17626?source=see_link\">",
"     \"Pharmacotherapy for smoking cessation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Multidisciplinary approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;In recognition of the chronic nature of tobacco dependence, a chronic care model, where a multidisciplinary, team-based approach is used, has been implemented with successful abstinence rates in observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12904/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. Utilizing other members of the care team, as well as making use of electronic systems to flag a patient's active smoking status, and more conversations between patients and clinicians can occur during office visits as part of an overall strategy for a team approach to care. A study that looked at the impact of adding smoking-related vital sign questions to patients' electronic records found that clinician-documented smoking cessation counseling rates were significantly increased [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12904/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other studies have looked at non-clinician-based systems approaches to enhancing smoking cessation rates [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12904/abstract/40\">",
"     40",
"    </a>",
"    ]. For instance, one study found that incorporating a smoking cessation template into electronic notes and providing patient education during referrals to clinical pharmacists was an effective method to enhance smoking cessation rates [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12904/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     RELAPSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relapse after an attempt at smoking cessation is common. Most smokers make many attempts to quit before they achieve success. Relapse is discussed in further detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link&amp;anchor=H13313734#H13313734\">",
"     \"Overview of smoking cessation management in adults\", section on 'Difficulty quitting and relapse'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The availability of over-the-counter smoking cessation aides means that clinicians will see an increasing number of smokers who have already made multiple unsuccessful attempts to quit. These patients may be highly dependent upon nicotine, making it even more imperative that the clinician be knowledgeable about available treatment options and resources.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Relapse prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most relapses occur soon after a person quits smoking, yet some people relapse months or even years after the quit date. All clinicians should work to prevent relapse. Relapse prevention programs can take the form of either minimal (brief) or more intensive programs (",
"    <a class=\"graphic graphic_table graphicRef54759 \" href=\"UTD.htm?43/36/44620\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There is relatively little evidence that specific interventions prevent relapse after smoking cessation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12904/abstract/42\">",
"     42",
"    </a>",
"    ]; however, it is reasonable to try simple interventions that promote abstinence. The clinician should take every opportunity to encourage and congratulate the patient on quitting. The benefits of smoking cessation can be highlighted by simply asking how their lives have changed since they stopped smoking. An equally important step is to address any problems encountered as a result of abstinence (eg, weight gain, depression, or change in relationships with other smoking friends or relatives).",
"   </p>",
"   <p>",
"    Relapse prevention should be part of every encounter with a patient who has quit recently.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Management of relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most smokers make many attempts to quit before they achieve success. Smokers should be made aware of this when they are attempting to quit, and when they have relapsed after a quit attempt.",
"   </p>",
"   <p>",
"    The clinician should assess for nonadherence or improper use of cessation aides when a patient who has quit smoking relapses. Determine the patient's insight into the possible reasons why the attempt failed and explore solutions for the next quit attempt. Screen and treat comorbid conditions that may affect relapse such as depression",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chemical dependency other than nicotine.",
"   </p>",
"   <p>",
"    Consider referral to a subspecialty clinic or smoking cessation program for the smoker who is heavily dependent upon nicotine or has had multiple unsuccessful attempts. Different types of providers (physicians, nurses, psychologists, dentists) can improve smoking cessation rates; involving multiple types of providers may enhance success. Intensive individual and group counseling also is often effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given conditions. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/46/18146?source=see_link\">",
"       \"Patient information: Quitting smoking (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"       \"Patient information: Quitting smoking (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tobacco dependence is a chronic condition that often requires repeated intervention. Effective treatments, including individual, group, and telephone counseling, can produce long-term or even permanent abstinence. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Background'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Every patient who uses tobacco should be offered smoking cessation strategies on every primary care visit. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Assessment of use and exposure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who use tobacco but are unwilling to quit should be approached with the \"5 R's\" of motivational intervention (Relevance, Risks, Rewards, Roadblocks, and Repetition) (",
"      <a class=\"graphic graphic_table graphicRef70628 \" href=\"UTD.htm?17/58/18349\">",
"       table 2",
"      </a>",
"      ). Smokers may be unwilling to quit due to misinformation, concern about the effects of quitting, or demoralization because of previous unsuccessful quit attempts. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Enhancing the motivation to quit'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Patients who use tobacco and are willing to quit should be managed using the \"5 A's\" (Ask, Advise, Assess, Assist, and Arrange) (",
"      <a class=\"graphic graphic_table graphicRef74402 \" href=\"UTD.htm?40/33/41500\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef52690 \" href=\"UTD.htm?39/23/40316\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Counseling'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Provision of practical counseling (problem",
"      <span class=\"nowrap\">",
"       solving/skills",
"      </span>",
"      training) and social support are effective approaches that should be offered to patients who are attempting tobacco cessation. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Treatment strategies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatments involving person-to-person contact (individual, group, or proactive telephone counseling) are consistently effective, and their effectiveness increases with treatment intensity. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Counseling'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most smokers make many attempts to quit before they achieve success. Smokers should be made aware of this when they are attempting to quit. Relapse prevention strategies should be applied to patients who have recently quit using tobacco (",
"      <a class=\"graphic graphic_table graphicRef54759 \" href=\"UTD.htm?43/36/44620\">",
"       table 5",
"      </a>",
"      ). As an example, any problems encountered as a result of abstinence (eg, weight gain, depression) should be addressed promptly. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Relapse prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Consider referral to a specialty clinic or smoking cessation program for the smoker who is heavily dependent upon nicotine or has had multiple unsuccessful attempts. Many different types of providers can improve smoking cessation rates once relapse occurs. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Multidisciplinary approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12904/abstract/1\">",
"      Lancaster T, Stead L. Physician advice for smoking cessation. Cochrane Database Syst Rev 2004; :CD000165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12904/abstract/2\">",
"      Tomar SL, Husten CG, Manley MW. Do dentists and physicians advise tobacco users to quit? J Am Dent Assoc 1996; 127:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12904/abstract/3\">",
"      Centers for Disease Control and Prevention (CDC). Cigarette smoking among adults--United States, 1999. MMWR Morb Mortal Wkly Rep 2001; 50:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12904/abstract/4\">",
"      Ockene JK. Physician-delivered interventions for smoking cessation: strategies for increasing effectiveness. Prev Med 1987; 16:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12904/abstract/5\">",
"      Anda RF, Remington PL, Sienko DG, Davis RM. Are physicians advising smokers to quit? The patient's perspective. JAMA 1987; 257:1916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12904/abstract/6\">",
"      A clinical practice guideline for treating tobacco use and dependence: A US Public Health Service report. The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives. JAMA 2000; 283:3244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12904/abstract/7\">",
"      Practice guideline for the treatment of patients with nicotine dependence. American Psychiatric Association. Am J Psychiatry 1996; 153:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12904/abstract/8\">",
"      Robinson MD, Laurent SL, Little JM Jr. Including smoking status as a new vital sign: it works! J Fam Pract 1995; 40:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12904/abstract/9\">",
"      Okuyemi KS, Ahluwalia JS, Wadland WC. The evaluation and treatment of tobacco use disorder. J Fam Pract 2001; 50:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12904/abstract/10\">",
"      Law M, Tang JL. An analysis of the effectiveness of interventions intended to help people stop smoking. Arch Intern Med 1995; 155:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12904/abstract/11\">",
"      Hughes JR, Goldstein MG, Hurt RD, Shiffman S. Recent advances in the pharmacotherapy of smoking. JAMA 1999; 281:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12904/abstract/12\">",
"      Solberg LI, Boyle RG, Davidson G, et al. Patient satisfaction and discussion of smoking cessation during clinical visits. Mayo Clin Proc 2001; 76:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12904/abstract/13\">",
"      Parkes G, Greenhalgh T, Griffin M, Dent R. Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial. BMJ 2008; 336:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12904/abstract/14\">",
"      Bize R, Burnand B, Mueller Y, et al. Biomedical risk assessment as an aid for smoking cessation. Cochrane Database Syst Rev 2009; :CD004705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12904/abstract/15\">",
"      Smith SS, McCarthy DE, Japuntich SJ, et al. Comparative effectiveness of 5 smoking cessation pharmacotherapies in primary care clinics. Arch Intern Med 2009; 169:2148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12904/abstract/16\">",
"      Ranney L, Melvin C, Lux L, et al. Systematic review: smoking cessation intervention strategies for adults and adults in special populations. Ann Intern Med 2006; 145:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12904/abstract/17\">",
"      Anda RF, Williamson DF, Escobedo LG, et al. Depression and the dynamics of smoking. A national perspective. JAMA 1990; 264:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12904/abstract/18\">",
"      Lipkus IM, Barefoot JC, Williams RB, Siegler IC. Personality measures as predictors of smoking initiation and cessation in the UNC Alumni Heart Study. Health Psychol 1994; 13:149.",
"     </a>",
"    </li>",
"    <li>",
"     Fiore MC, Jaen CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update. Clinical practice guideline. Available at: www.surgeongeneral.gov/tobacco/treating_tobacco_use08.pdf (Accessed on September 30, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12904/abstract/20\">",
"      Coleman T. ABC of smoking cessation. Use of simple advice and behavioural support. BMJ 2004; 328:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12904/abstract/21\">",
"      Lancaster T, Stead LF. Self-help interventions for smoking cessation. Cochrane Database Syst Rev 2005; :CD001118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12904/abstract/22\">",
"      Stead LF, Perera R, Lancaster T. Telephone counselling for smoking cessation. Cochrane Database Syst Rev 2006; :CD002850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12904/abstract/23\">",
"      Sood A, Andoh J, Verhulst S, et al. \"Real-world\" effectiveness of reactive telephone counseling for smoking cessation: a randomized controlled trial. Chest 2009; 136:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12904/abstract/24\">",
"      Miller N, Frieden TR, Liu SY, et al. Effectiveness of a large-scale distribution programme of free nicotine patches: a prospective evaluation. Lancet 2005; 365:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12904/abstract/25\">",
"      Whittaker R, Borland R, Bullen C, et al. Mobile phone-based interventions for smoking cessation. Cochrane Database Syst Rev 2009; :CD006611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12904/abstract/26\">",
"      Free C, Knight R, Robertson S, et al. Smoking cessation support delivered via mobile phone text messaging (txt2stop): a single-blind, randomised trial. Lancet 2011; 378:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12904/abstract/27\">",
"      Abroms LC, Padmanabhan N, Thaweethai L, Phillips T. iPhone apps for smoking cessation: a content analysis. Am J Prev Med 2011; 40:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12904/abstract/28\">",
"      Myung SK, McDonnell DD, Kazinets G, et al. Effects of Web- and computer-based smoking cessation programs: meta-analysis of randomized controlled trials. Arch Intern Med 2009; 169:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12904/abstract/29\">",
"      Civljak M, Sheikh A, Stead LF, Car J. Internet-based interventions for smoking cessation. Cochrane Database Syst Rev 2010; :CD007078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12904/abstract/30\">",
"      Stead LF, Lancaster T. Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst Rev 2005; :CD001007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12904/abstract/31\">",
"      Spice P. Setting up a cessation service. BMJ 2004; 328:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12904/abstract/32\">",
"      Jamrozik K. Population strategies to prevent smoking. BMJ 2004; 328:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12904/abstract/33\">",
"      Marcus BH, Albrecht AE, King TK, et al. The efficacy of exercise as an aid for smoking cessation in women: a randomized controlled trial. Arch Intern Med 1999; 159:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12904/abstract/34\">",
"      Ussher M. Exercise interventions for smoking cessation. Cochrane Database Syst Rev 2005; :CD002295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12904/abstract/35\">",
"      Lancaster T, Stead LF. Self-help interventions for smoking cessation. Cochrane Database Syst Rev 2002; :CD001118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12904/abstract/36\">",
"      Richards D, Toop L, Brockway K, et al. Improving the effectiveness of smoking cessation in primary care: lessons learned. N Z Med J 2003; 116:U417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12904/abstract/37\">",
"      Zwar N, Richmond R, Halcomb E, et al. Quit in general practice: a cluster randomised trial of enhanced in-practice support for smoking cessation. BMC Fam Pract 2010; 11:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12904/abstract/38\">",
"      Mariano ME, Elia D, Scarascia A, et al. Smoking cessation: aspects of prevention and therapy. The activity of the Smoking Cessation Center of Parma-Italy. Acta Biomed 2009; 80:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12904/abstract/39\">",
"      McCullough A, Fisher M, Goldstein AO, et al. Smoking as a vital sign: prompts to ask and assess increase cessation counseling. J Am Board Fam Med 2009; 22:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12904/abstract/40\">",
"      Boyle R, Solberg L, Fiore M. Use of electronic health records to support smoking cessation. Cochrane Database Syst Rev 2011; :CD008743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12904/abstract/41\">",
"      Ragucci KR, Shrader SP. A method for educating patients and documenting smoking status in an electronic medical record. Ann Pharmacother 2009; 43:1616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12904/abstract/42\">",
"      Lancaster T, Hajek P, Stead LF, et al. Prevention of relapse after quitting smoking: a systematic review of trials. Arch Intern Med 2006; 166:828.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6920 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-ECB61E16A9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_38_12904=[""].join("\n");
var outline_f12_38_12904=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ASSESSMENT OF USE AND EXPOSURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ENHANCING THE MOTIVATION TO QUIT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TREATMENT STRATEGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Counseling",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H125250936\">",
"      - Clinician counseling",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H149731929\">",
"      - Telephone counseling",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H125250234\">",
"      - Mobile phone interventions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H125250241\">",
"      - Computer-based interventions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H125250248\">",
"      - Group therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Problem solving/skills training",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pharmacologic therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Multidisciplinary approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      RELAPSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Relapse prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Management of relapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6920\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6920|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/33/41500\" title=\"table 1\">",
"      Five As for smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/58/18349\" title=\"table 2\">",
"      Five Rs smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/23/40316\" title=\"table 3\">",
"      Assisting patients with smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/28/44491\" title=\"table 4\">",
"      Abstinence rates by length of counseling session",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/36/44620\" title=\"table 5\">",
"      Preventing and managing smoking relapse",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=related_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/46/18146?source=related_link\">",
"      Patient information: Quitting smoking (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/13/17626?source=related_link\">",
"      Pharmacotherapy for smoking cessation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22505?source=related_link\">",
"      Secondhand smoke exposure: Effects in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_38_12905="Use of beta blockers in heart failure due to systolic dysfunction";
var content_f12_38_12905=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Use of beta blockers in heart failure due to systolic dysfunction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/38/12905/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/38/12905/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/38/12905/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/38/12905/contributors\">",
"     Stephen S Gottlieb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/38/12905/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/38/12905/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/38/12905/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials have shown that blockade of beta adrenergic receptors leads to symptomatic improvement, reduced hospitalization and enhanced survival in many patients with heart failure (HF) and systolic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12905/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Therefore, beta blockers are an important component of standard HF therapy in patients with current or prior symptoms of HF and depressed left ventricular (LV) systolic function.",
"   </p>",
"   <p>",
"    Recommendations for the use of beta blockers in heart failure due to systolic dysfunction are presented here. The rationale for and clinical trials of beta blockers in HF due to systolic dysfunction, an overview of the treatment of heart failure (HF) due to systolic dysfunction (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ), and the possible role of beta blockers in asymptomatic left ventricular dysfunction and in patients with diastolic dysfunction are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36282?source=see_link\">",
"     \"Rationale for and clinical trials of beta blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28601?source=see_link\">",
"     \"Evaluation and management of asymptomatic left ventricular systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=see_link\">",
"     \"Treatment and prognosis of diastolic heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL BENEFIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blocker trials in patients with HF due to systolic dysfunction have demonstrated reductions in mortality, hospitalization rates and symptoms. A number of major trials have demonstrated a survival benefit with several beta blockers (sustained release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    succinate,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/29/2520?source=see_link\">",
"     bisoprolol",
"    </a>",
"    ) in selected patients with HF.",
"   </p>",
"   <p>",
"    The range of benefit can be illustrated by findings from a meta-analysis that included 22 trials involving more than 10,000 patients with left ventricular ejection fraction (LVEF) &lt;35 to 45 percent, almost all of whom had NYHA class II or III HF and were also treated with ACE inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12905/abstract/1\">",
"     1",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beta blockers significantly reduced total mortality at one year (odds ratio 0.65, 95% CI 0.53-0.80) and two years (odds ratio 0.72, 95% CI 0.61-0.84). Assuming a mortality rate of 12 percent in the placebo group at one year (derived from the three largest and most recent trials), beta blocker therapy saved 3.8 lives in the first year per 100 patients treated.",
"     </li>",
"     <li>",
"      Beta blockers also reduced hospitalization for HF (odds ratio 0.64, 95% CI 0.53-0.79) with an absolute benefit of four fewer hospitalizations in the first year per 100 patients treated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar findings were noted in a meta-analysis limited to large randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12905/abstract/2\">",
"     2",
"    </a>",
"    ]. Clinical trials of beta blocker therapy are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36282?source=see_link\">",
"     \"Rationale for and clinical trials of beta blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Symptomatic benefit (such as improvement in symptoms scores, NYHA functional class, and exercise tolerance) has been observed in randomized trials comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    <span class=\"nowrap\">",
"     CR/XL",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12905/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Major society guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major societies have issued similar recommendations regarding the use of beta blockers in HF due to systolic dysfunction.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The 2005",
"      <span class=\"nowrap\">",
"       ACC/AHA",
"      </span>",
"      guidelines recommended beta blockers in patients with current or prior symptoms of HF and left ventricular systolic dysfunction (",
"      <a class=\"graphic graphic_table graphicRef81590 graphicRef80859 \" href=\"UTD.htm?31/18/32046\">",
"       table 2A-B",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?12/38/12905/abstract/3\">",
"       3",
"      </a>",
"      ]. This recommendation was unchanged by the 2009 focused update. Symptomatic patients should have no or minimal evidence of fluid retention, be on an ACE inhibitor, and should not have required recent intravenous inotropic therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link&amp;anchor=H14#H14\">",
"       \"Overview of the therapy of heart failure due to systolic dysfunction\", section on 'ACE inhibitors or beta blockers first'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The 2006 Heart Failure Society of America (HFSA) guidelines included similar recommendations for patients with HF and an LVEF &le;40 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?12/38/12905/abstract/7\">",
"       7",
"      </a>",
"      ]. Initiation in stable patients in hospital prior to discharge is recommended when possible.",
"     </li>",
"     <li>",
"      The 2008 European Society of Cardiology (ESC) guidelines recommended beta blocker therapy in patients with NYHA functional class II to IV HF and an LVEF &le;40 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?12/38/12905/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Our recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of a contraindication, we recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    , extended release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    succinate, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/29/2520?source=see_link\">",
"     bisoprolol",
"    </a>",
"    for patients with current or prior HF and an LVEF &le;40 percent. These patients should also be treated with an ACE inhibitor, salt restriction and diuretics as needed for fluid retention, as well as other therapies as indicated (",
"    <a class=\"graphic graphic_table graphicRef81590 graphicRef80859 \" href=\"UTD.htm?31/18/32046\">",
"     table 2A-B",
"    </a>",
"    ). Beta blockers with intrinsic sympathomimetic activity should be",
"    <strong>",
"     avoided",
"    </strong>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12905/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Relative contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The controlled trials of beta blocker therapy excluded patients with absolute or relative contraindications to beta blocker use [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12905/abstract/1\">",
"     1",
"    </a>",
"    ]. Relative contraindications in patients with HF include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Heart rate &lt;60 bpm",
"     </li>",
"     <li>",
"      Symptomatic hypotension",
"     </li>",
"     <li>",
"      Greater than minimal evidence of fluid retention",
"     </li>",
"     <li>",
"      Signs of peripheral hypoperfusion",
"     </li>",
"     <li>",
"      PR interval &gt;0.24 sec",
"     </li>",
"     <li>",
"      Second- or third-degree atrioventricular block",
"     </li>",
"     <li>",
"      History of asthma or reactive airways",
"     </li>",
"     <li>",
"      Peripheral artery disease with resting limb ischemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ADMINISTRATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Initiation of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before therapy is initiated, the patient should be informed that beta blockers may lead to an initial increase in symptoms. However, initiation of low doses and careful follow-up should minimize these effects. Guidelines for the safe initiation of therapy have been published [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12905/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to initiation of therapy, the patient should have no or minimal evidence of fluid retention and should not have required recent intravenous inotropic therapy.",
"   </p>",
"   <p>",
"    An ACE inhibitor is generally instituted before beta blocker therapy. The preference for this approach is largely based upon clinical trials with ACE inhibitors being performed before trials of beta blockers. However, subsequent randomized trials (eg, CIBIS III) suggest that the outcomes may be similar if beta blockers are given first. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\", section on 'ACE inhibitors or beta blockers first'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The results from the IMPACT-HF trial and the OPTIMIZE-HF registry support the initiation of a beta blocker in stable patients prior to hospital discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12905/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The IMPACT-HF demonstrated that the initiation of beta blockade in the hospital, compared to later initiation, was associated with more frequent use of beta blockers at 60 days without any increase in the rates of worsening HF, hypotension, bradycardia, or drug discontinuation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12905/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Choice of beta blocker",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/29/2520?source=see_link\">",
"     bisoprolol",
"    </a>",
"    , or extended release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    succinate since these beta blockers have been shown to reduce all-cause mortality and decrease hospitalization in patients with HF and left ventricular systolic dysfunction (LVEF &le; 35-40 percent) in randomized controlled trials.",
"   </p>",
"   <p>",
"    Limited data are available on the comparative efficacy of these three beta blockers. Indirect evidence suggests that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    may produce greater improvement in LVEF than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    . Patients with low blood pressure may be less likely to tolerate carvedilol because of its vasodilatory activity. Conversely, carvedilol may be preferred in patients with higher blood pressure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36282?source=see_link&amp;anchor=H18#H18\">",
"     \"Rationale for and clinical trials of beta blockers in heart failure due to systolic dysfunction\", section on 'Comparison with other beta blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A network meta-analysis of randomized trial data as well as observational data have suggested that the beneficial effect of beta blocker therapy in systolic heart failure may be a class effect [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12905/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Observational data suggest that some beta blockers other than those with proven benefit in randomized trials (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    ) may be beneficial in HF. However, these observations are not sufficient to support a recommendation for use of beta blockers without benefit established by randomized studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy should be begun in",
"    <strong>",
"     very low doses",
"    </strong>",
"    and the dose doubled at regular intervals (eg, every two to three weeks) until the target dose is reached or symptoms become limiting [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12905/abstract/14\">",
"     14",
"    </a>",
"    ]. Initial and target doses are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"       carvedilol",
"      </a>",
"      , 3.125 mg twice daily with target dose of 25 to 50 mg twice daily (the higher dose being used in subjects over 85 kg)",
"     </li>",
"     <li>",
"      For extended release",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      succinate, 12.5 or 25 mg daily with target dose of 200",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"     </li>",
"     <li>",
"      For",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/29/2520?source=see_link\">",
"       bisoprolol",
"      </a>",
"      , 1.25 mg once daily with target dose of 5 to 10 mg once daily",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The patient should weigh himself or herself daily and call the physician if there has been a 1 to 1.5 kg weight gain. Weight gain alone may be treated with diuretics, but resistant edema or more severe decompensation may require beta blocker dose reduction or cessation (possibly transient). (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Worsening of HF symptoms'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Every effort should be made to achieve the target dose. The proportion of patients who reach the target dose is higher in clinical trials than in the general population in which the patients are older and have more comorbid disease. However, although not optimal, even low doses appear to be of benefit and should be used when higher doses are not tolerated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4565827\">",
"    <span class=\"h3\">",
"     Switching beta blocker",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data are available to guide switching from a beta blocker that is not recommended for HF to a recommended one, or switching among the three recommended beta blockers. Any switch must be performed with caution since the drugs have differing mechanisms of action and pharmacokinetics.",
"   </p>",
"   <p>",
"    A reasonable approach is to switch to the equivalent percentage (or less) of the maximum dose of beta blocker. For example, commonly used maximum doses are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    25 mg twice daily,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    succinate 200 mg daily and metoprolol tartrate 100 mg twice daily (the last is not recommended for HF). Thus, it would be reasonable to switch from metoprolol tartrate 50 mg twice daily to carvedilol 12.5 twice daily. The carvedilol dose should subsequently be titrated as indicated.",
"   </p>",
"   <p>",
"    Administration of the new drug should be delayed at least until the next dose of the terminated dose would have been scheduled (eg, 12 hours after the last dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    tartrate or 24 hours after the last dose of metoprolol succinate).",
"   </p>",
"   <p>",
"    Observations from the post-study phase of the COMET trial indicated that a similar approach to switching between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    was practical and well-tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12905/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although evidence establishing the optimum duration of beta blocker therapy in HF are lacking, available data support continuation of beta blocker therapy in patients with left ventricular systolic dysfunction and history of HF [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12905/abstract/3,16,17\">",
"     3,16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Use with other HF drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACE inhibitors, angiotensin II receptor blockers (ARBs), and aldosterone antagonists, as well as combination",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    and nitrate therapy in blacks, improve survival in patients with HF due to systolic dysfunction. The benefit from each of these drugs appears to be additive to that of beta blockers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36282?source=see_link\">",
"     \"Rationale for and clinical trials of beta blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     ACE inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of HF with ACE inhibitor and beta blocker combination therapy is more effective than use of either therapy alone (",
"    <a class=\"graphic graphic_figure graphicRef70054 \" href=\"UTD.htm?28/9/28829\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12905/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     ARBs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination therapy with an ARB and a beta blocker appears to be more effective than either agent alone [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12905/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2680?source=see_link\">",
"     \"Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are conflicting data on the value of adding an ARB to patients already treated with an ACE inhibitor and beta blocker [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12905/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. We regard the data supporting addition of ARB therapy as more definitive. We suggest the addition of an ARB, if tolerated, to a regimen including ACE inhibitors and beta blockers, in patients with persistent class II to III HF if the patient has normal renal function and low to normal serum potassium. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2680?source=see_link\">",
"     \"Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Aldosterone antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence from the EPHESUS and RALES trials supports a benefit of aldosterone antagonists in patients taking beta blockers [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12905/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Similarly, patients taking an aldosterone antagonist appear to benefit from addition of beta blocker therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12905/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28521?source=see_link\">",
"     \"Use of aldosterone antagonists in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Hydralazine plus nitrate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence from the AHeFT trial supports a benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    plus nitrate therapy in African American patients taking beta blockers [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12905/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Use with aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some concern has been raised that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    may interfere with treatment of HF although evidence for such an interaction is limited.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A post hoc analysis suggested that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      use may reduce the beneficial impact of beta blocker (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"       carvedilol",
"      </a>",
"      ) therapy on LVEF [",
"      <a class=\"abstract\" href=\"UTD.htm?12/38/12905/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A potential interaction between",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and ACE inhibitors has also been investigated. However, most of the available evidence does not support an inhibitory effect of aspirin on the long-term outcome benefits of ACE inhibitors in HF. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=see_link\">",
"       \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the demonstrated value of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and the confounding features of available evidence, it would be premature to modify recommendations for aspirin use until further data are available.",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/3/42039?source=see_link&amp;anchor=H6#H6\">",
"     \"Drugs that should be avoided or used with caution in patients with heart failure\", section on 'Aspirin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential side effects of beta blockers include worsening of HF, bradycardia, hypotension, bronchospasm, and exacerbation of peripheral vascular disease. Concern about adverse effects of beta blockade may deter clinicians from prescribing them despite the recognized benefits [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12905/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3704?source=see_link\">",
"     \"Major side effects of beta blockers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The rate of withdrawal of beta blockers during the run-in period in clinical HF trials has been about 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12905/abstract/1\">",
"     1",
"    </a>",
"    ]. The overall all-cause withdrawal rate for patients on active therapy has been 16 percent, which is actually less than that seen among placebo recipients (18 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12905/abstract/29\">",
"     29",
"    </a>",
"    ]. Side effects that have been significantly more common with beta blockers in clinical trials are dizziness (22 versus 17 percent with placebo) and bradycardia (6 versus 2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12905/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Worsening of HF symptoms",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     During beta blocker initiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients may have a period of worsening of HF symptoms lasting two weeks to two months after the initiation of beta blocker therapy. This is minimized by starting at extremely low doses and titrating up every two weeks until target doses are reached.",
"   </p>",
"   <p>",
"    The chief factor limiting titration is bradycardia. Adverse effects appear decreased after two months of beta blocker administration [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12905/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Similarly, a low rate of adverse events during",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"       carvedilol",
"      </a>",
"      initiation was observed in an analysis of COPERNICUS trial of patients with class III to IV HF [",
"      <a class=\"abstract\" href=\"UTD.htm?12/38/12905/abstract/30,31\">",
"       30,31",
"      </a>",
"      ]. During the first eight weeks of the trial (the dose initiation and titration period), the rate of death or hospitalization for any reason was not higher in the carvedilol group than the placebo group (12.3 versus 14.4 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/38/12905/abstract/31\">",
"       31",
"      </a>",
"      ]. During the first eight weeks, the carvedilol arm was comparable to the placebo arm in the rate of worsening HF (5.1 versus 6.4 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The low rates of worsening HF are likely due to the requirement for clinical euvolemia before enrollment and vigorous efforts to maintain euvolemia during the trial. Furthermore, the investigators who managed trial patients were highly experienced in the treatment of HF. Cautious management is important in the initiation of beta blocker therapy, especially in patients with advanced HF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     During maintenance therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A separate issue is the management of an exacerbation of HF in a patient who has been stable on a beta blocker for more than three months. Given the benefits of beta blockade, the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines and many cardiologists recommend continuing the beta blocker and intensifying diuretics and other therapies if the exacerbation is primarily due to fluid overload without hemodynamic instability [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12905/abstract/3,32\">",
"     3,32",
"    </a>",
"    ]. On the other hand, temporary cessation of beta blocker therapy is reasonable if the exacerbation is characterized by hypoperfusion, bradycardia, or the requirement for inotropic drugs. Inotropes that act independent of the beta adrenergic receptor, such as the phosphodiesterase inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3366?source=see_link\">",
"     milrinone",
"    </a>",
"    , may be preferable in this setting. Reintroduction of the beta blocker is warranted if the patient stabilizes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41079?source=see_link\">",
"     \"Treatment of acute decompensated heart failure: General considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Other adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of adverse effects of beta blockade other than exacerbation of HF has been small in clinical trials. In a pooled analysis of nine studies, side effects caused more often by beta blockers than placebo included hypotension (7.6 versus 6.1 percent), dizziness (21.5 versus 16.6 percent), and bradycardia (5.7 versus 1.8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12905/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If symptomatic hypotension develops with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    , a trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    succinate or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/29/2520?source=see_link\">",
"     bisoprolol",
"    </a>",
"    should be considered. A reduction in dose of other hypotensive agents (other than ACE inhibitors or ARBs) such as nitrates and diuretics should be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12905/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SPECIFIC PATIENT SUBSETS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Less evidence is available to support beta blocker use in specific patients subsets. As recommended in the 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines, groups of patients including high-risk ethnic minorities (eg, blacks), groups underrepresented in clinical trials, and any groups believed to be underserved should, in the absence of specific evidence to the contrary, receive therapy identical to that applied to the broader population [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12905/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Available evidence supports beta blocker use for treatment of HF due to systolic dysfunction in patients with ischemic and nonischemic cardiomyopathies, stable class IV HF, diabetes, women, blacks, and elderly patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Use in ischemic and nonischemic cardiomyopathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trials have demonstrated that improvements in exercise duration, stabilization of LV function, and mortality are similar in ischemic and nonischemic cardiomyopathies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12905/abstract/33-35\">",
"     33-35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Class IV HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mortality benefit of beta blockade appears to extend to patients with severe class III and stable class IV HF (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12905/abstract/4,5,30\">",
"     4,5,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Combination with dobutamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with advanced HF who decompensate may be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    . In this setting, pretreatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    markedly reduced the inotropic response to dobutamine, whereas",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    had only a slight inhibitory effect [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12905/abstract/36\">",
"     36",
"    </a>",
"    ]. Alternatively, use of inotropes that act independent of the beta adrenergic receptor, such as the phosphodiesterase inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3366?source=see_link\">",
"     milrinone",
"    </a>",
"    , may be preferable in this setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/37/7769?source=see_link\">",
"     \"Inotropic agents in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Use in women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women have been underrepresented in the beta blocker trials, but appear to benefit to the same degree as men [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12905/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Use in blacks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blocker use in black HF patients is supported by data from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    succinate and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/29/2520?source=see_link\">",
"     bisoprolol",
"    </a>",
"    HF trials [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12905/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Results from the BEST trial suggest that bucindolol, a beta blocker with partial beta agonist activity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12905/abstract/40\">",
"     40",
"    </a>",
"    ], may have differing effects in white and black HF patients. In the BEST trial there was no significant mortality benefit in the treatment group as a whole or in black patients although there was a significant benefit in white patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12905/abstract/41\">",
"     41",
"    </a>",
"    ]. However, results of subgroup analysis should be interpreted with caution given the potential effect of chance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36282?source=see_link&amp;anchor=H34#H34\">",
"     \"Rationale for and clinical trials of beta blockers in heart failure due to systolic dysfunction\", section on 'Use in blacks'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Use in diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a meta-analysis including 1883 diabetics and 7042 nondiabetics, the survival benefit with beta blocker therapy was significant for both those with diabetes and for those without (relative risk 0.77 and 0.65, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12905/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28569?source=see_link&amp;anchor=H13#H13\">",
"     \"Heart failure in diabetes mellitus\", section on 'Therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Use in patients with COPD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta-1 selective beta blockers (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    ) appear to be safe in patients with COPD, even when there is a bronchospastic component. In a meta-analysis of major trials, no changes in FEV1, respiratory symptoms, or the use of inhaled beta agonists were seen [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12905/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. More limited data suggest that non-specific beta blockade (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    ) may be safe in the setting of COPD as well, but less well tolerated in patients with asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12905/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Use in elderly adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;All of the major randomized trials included many elderly patients who appeared to derive similar benefit as younger patients.",
"   </p>",
"   <p>",
"    The SENIORS trial evaluated the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/34/32295?source=see_link\">",
"     nebivolol",
"    </a>",
"    , a novel beta 1 blocker (and beta 3 agonist) with vasodilating activity in patients &ge;70 years of age with history of hospital admission for HF within the previous year OR known LVEF (&le;35 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12905/abstract/45\">",
"     45",
"    </a>",
"    ]. Nebivolol therapy produced a significant reduction in the primary end point of all-cause mortality or cardiovascular hospital admission and there was a trend toward decrease in all-cause mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36282?source=see_link&amp;anchor=H37#H37\">",
"     \"Rationale for and clinical trials of beta blockers in heart failure due to systolic dysfunction\", section on 'Use in elderly adults'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Use in patients on hemodialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Available evidence including a small randomized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    trial suggests that beta blocker therapy is beneficial in dialysis patients with HF due to systolic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12905/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26584?source=see_link&amp;anchor=H10#H10\">",
"     \"Myocardial dysfunction in end-stage renal disease\", section on 'Therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=see_link\">",
"       \"Patient information: Heart failure (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use of certain beta blockers in patients with HF due to systolic dysfunction, particularly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"       carvedilol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      succinate, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/29/2520?source=see_link\">",
"       bisoprolol",
"      </a>",
"      , reduces hospitalizations for HF and improves survival. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical benefit'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Available evidence also supports beta blocker use for treatment of HF due to systolic dysfunction in subgroups including patients with ischemic and nonischemic cardiomyopathies, stable class IV HF, women, blacks, patients with diabetes, and elderly adults.",
"     </li>",
"     <li>",
"      In patients with current or prior HF and an LVEF &le;40 percent, we recommend therapy with a beta blocker (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We believe that clinicians should choose one of the beta blockers of proven benefit (including reduction in all-cause mortality) in randomized trials (ie,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"       carvedilol",
"      </a>",
"      , extended release",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      succinate, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/29/2520?source=see_link\">",
"       bisoprolol",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Prior to initiation of therapy, the patient should have no or minimal evidence of fluid retention. Beta blocker therapy should be initiated in stable patients prior to hospital discharge.",
"     </li>",
"     <li>",
"      Beta blocker therapy provides incremental benefit in patients with HF treated with an ACE inhibitor or ARB or aldosterone antagonist. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Use with other HF drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ACE inhibitor therapy should generally be instituted before beta blocker therapy is initiated. Data supporting initiation of beta blocker therapy first are limited.",
"     </li>",
"     <li>",
"      Beta blocker therapy should be begun at",
"      <strong>",
"       very low doses",
"      </strong>",
"      and the dose doubled at regular intervals (for example, every two to three weeks) until the target dose is reached or symptoms (worsening HF) become limiting or symptomatic hypotension or excessive bradycardia (rate &lt;50",
"      <span class=\"nowrap\">",
"       beats/min)",
"      </span>",
"      develops. Initial and target doses are:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"       carvedilol",
"      </a>",
"      , 3.125 mg twice daily; target of 25 to 50 mg twice daily (the higher dose being used in subjects over 85 kg)",
"     </li>",
"     <li>",
"      For extended release",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      , 12.5 or 25 mg daily; target of 200",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"     </li>",
"     <li>",
"      For",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/29/2520?source=see_link\">",
"       bisoprolol",
"      </a>",
"      , 1.25 mg once daily; target of 5 to 10 mg once daily",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Every effort should be made to achieve the target doses through individualized dose titration. When target doses are not tolerated, even low doses appear to be of benefit, although they are not optimal.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12905/abstract/1\">",
"      Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Ann Intern Med 2001; 134:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12905/abstract/2\">",
"      Foody JM, Farrell MH, Krumholz HM. beta-Blocker therapy in heart failure: scientific review. JAMA 2002; 287:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12905/abstract/3\">",
"      Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12905/abstract/4\">",
"      Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002; 106:2194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12905/abstract/5\">",
"      Goldstein S, Fagerberg B, Kjekshus J, et al. Metoprolol controlled release/extended release in patients with severe heart failure: analysis of the experience in the MERIT-HF study. J Am Coll Cardiol 2001; 38:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12905/abstract/6\">",
"      Krum H, Sackner-Bernstein JD, Goldsmith RL, et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995; 92:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12905/abstract/7\">",
"      . Heart failure in patients with left ventricular systolic dysfunction. J Card Fail 2006; 12:e38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12905/abstract/8\">",
"      Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29:2388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12905/abstract/9\">",
"      Eichhorn EJ, Bristow MR. Practical guidelines for initiation of beta-adrenergic blockade in patients with chronic heart failure. Am J Cardiol 1997; 79:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12905/abstract/10\">",
"      Gattis WA, O'Connor CM, Gallup DS, et al. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. J Am Coll Cardiol 2004; 43:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12905/abstract/11\">",
"      Fonarow GC, Abraham WT, Albert NM, et al. Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: an analysis from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J 2007; 153:82.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12905/abstract/12\">",
"      Chatterjee S, Biondi-Zoccai G, Abbate A, et al. Benefits of &beta; blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ 2013; 346:f55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12905/abstract/13\">",
"      Go AS, Yang J, Gurwitz JH, et al. Comparative effectiveness of different beta-adrenergic antagonists on mortality among adults with heart failure in clinical practice. Arch Intern Med 2008; 168:2415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12905/abstract/14\">",
"      Gottlieb SS, Fisher ML, Kjekshus J, et al. Tolerability of beta-blocker initiation and titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Circulation 2002; 105:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12905/abstract/15\">",
"      Di Lenarda A, Remme WJ, Charlesworth A, et al. Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial). Eur J Heart Fail 2005; 7:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12905/abstract/16\">",
"      Morimoto S, Shimizu K, Yamada K, et al. Can beta-blocker therapy be withdrawn from patients with dilated cardiomyopathy? Am Heart J 1999; 138:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12905/abstract/17\">",
"      Eichhorn EJ. Beta-blocker withdrawal: the song of Orpheus. Am Heart J 1999; 138:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12905/abstract/18\">",
"      Exner DV, Dries DL, Waclawiw MA, et al. Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1999; 33:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12905/abstract/19\">",
"      Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12905/abstract/20\">",
"      McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12905/abstract/21\">",
"      Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345:1667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12905/abstract/22\">",
"      Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12905/abstract/23\">",
"      Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12905/abstract/24\">",
"      Krum H, Mohacsi P, Katus HA, et al. Are beta-blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS study. Am Heart J 2006; 151:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12905/abstract/25\">",
"      Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004; 351:2049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12905/abstract/26\">",
"      Taylor AL, Ziesche S, Yancy CW, et al. Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial. Circulation 2007; 115:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12905/abstract/27\">",
"      Lindenfeld J, Robertson AD, Lowes BD, et al. Aspirin impairs reverse myocardial remodeling in patients with heart failure treated with beta-blockers. J Am Coll Cardiol 2001; 38:1950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12905/abstract/28\">",
"      Chatterjee K. The fear of beta-blocker therapy in heart failure: time to forget. Arch Intern Med 2004; 164:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12905/abstract/29\">",
"      Ko DT, Hebert PR, Coffey CS, et al. Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials. Arch Intern Med 2004; 164:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12905/abstract/30\">",
"      Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12905/abstract/31\">",
"      Krum H, Roecker EB, Mohacsi P, et al. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. JAMA 2003; 289:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12905/abstract/32\">",
"      Farrell MH, Foody JM, Krumholz HM. beta-Blockers in heart failure: clinical applications. JAMA 2002; 287:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12905/abstract/33\">",
"      Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12905/abstract/34\">",
"      Bonet S, Agust&iacute; A, Arnau JM, et al. Beta-adrenergic blocking agents in heart failure: benefits of vasodilating and non-vasodilating agents according to patients' characteristics: a meta-analysis of clinical trials. Arch Intern Med 2000; 160:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12905/abstract/35\">",
"      Fisher ML, Gottlieb SS, Plotnick GD, et al. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. J Am Coll Cardiol 1994; 23:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12905/abstract/36\">",
"      Metra M, Nodari S, D'Aloia A, et al. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol 2002; 40:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12905/abstract/37\">",
"      Ghali JK, Pi&ntilde;a IL, Gottlieb SS, et al. Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). Circulation 2002; 105:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12905/abstract/38\">",
"      Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003; 41:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12905/abstract/39\">",
"      Yancy CW, Fowler MB, Colucci WS, et al. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med 2001; 344:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12905/abstract/40\">",
"      Andreka P, Aiyar N, Olson LC, et al. Bucindolol displays intrinsic sympathomimetic activity in human myocardium. Circulation 2002; 105:2429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12905/abstract/41\">",
"      Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001; 344:1659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12905/abstract/42\">",
"      Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for reversible airway disease. Cochrane Database Syst Rev 2002; :CD002992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12905/abstract/43\">",
"      Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med 2002; 137:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12905/abstract/44\">",
"      Kotlyar E, Keogh AM, Macdonald PS, et al. Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma. J Heart Lung Transplant 2002; 21:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12905/abstract/45\">",
"      Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12905/abstract/46\">",
"      Cice G, Ferrara L, Di Benedetto A, et al. Dilated cardiomyopathy in dialysis patients--beneficial effects of carvedilol: a double-blind, placebo-controlled trial. J Am Coll Cardiol 2001; 37:407.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3491 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-221.179.173.170-4115C7D097-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_38_12905=[""].join("\n");
var outline_f12_38_12905=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H36\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL BENEFIT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INDICATIONS FOR THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Major society guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Our recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Relative contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Initiation of therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Timing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Choice of beta blocker",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4565827\">",
"      - Switching beta blocker",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Use with other HF drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - ACE inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - ARBs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Aldosterone antagonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Hydralazine plus nitrate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Use with aspirin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Worsening of HF symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - During beta blocker initiation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - During maintenance therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Other adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SPECIFIC PATIENT SUBSETS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Use in ischemic and nonischemic cardiomyopathies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Class IV HF",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Combination with dobutamine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Use in women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Use in blacks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Use in diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Use in patients with COPD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Use in elderly adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Use in patients on hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3491\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3491|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/9/28829\" title=\"figure 1\">",
"      Mortality HF ACE beta block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3491|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/1/40989\" title=\"table 2A\">",
"      ACC AHA Rx systolic HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/45/42716\" title=\"table 2B\">",
"      ACC AHA Rx HF other diseases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=related_link\">",
"      ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2680?source=related_link\">",
"      Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/3/42039?source=related_link\">",
"      Drugs that should be avoided or used with caution in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28601?source=related_link\">",
"      Evaluation and management of asymptomatic left ventricular systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28569?source=related_link\">",
"      Heart failure in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/37/7769?source=related_link\">",
"      Inotropic agents in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3704?source=related_link\">",
"      Major side effects of beta blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26584?source=related_link\">",
"      Myocardial dysfunction in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=related_link\">",
"      Patient information: Heart failure (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36282?source=related_link\">",
"      Rationale for and clinical trials of beta blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=related_link\">",
"      Treatment and prognosis of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41079?source=related_link\">",
"      Treatment of acute decompensated heart failure: General considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28521?source=related_link\">",
"      Use of aldosterone antagonists in heart failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_38_12906="Minor head trauma in infants and children";
var content_f12_38_12906=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Minor head trauma in infants and children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/38/12906/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/38/12906/contributors\">",
"     Sara Schutzman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/38/12906/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/38/12906/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/38/12906/contributors\">",
"     Douglas R Nordli, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/38/12906/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/38/12906/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/38/12906/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Head trauma occurs commonly in childhood. Most head trauma in children is minor and not associated with brain injury or long-term sequelae. However, a small number of children who appear to be at low risk may have an intracranial injury.",
"   </p>",
"   <p>",
"    The goal of the evaluation of children with minor head trauma is to identify those with traumatic brain injury (TBI) and prevent deterioration and secondary injury, while limiting unnecessary radiographic procedures. Imaging, usually with computed tomography (CT), is highly sensitive for identifying brain injury requiring acute intervention. However, clinical predictors for intracranial injury are often nonspecific, particularly in young children.",
"   </p>",
"   <p>",
"    The epidemiology of head trauma in infants and children, the incidence of TBI, clinical features of head-injured children with and without brain injury, and the evaluation and management of infants and children with mild head trauma are presented here. Severe TBI in children and adolescents, concussion and mild head trauma in adolescents, and inflicted head trauma in children are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4250?source=see_link\">",
"     \"Initial approach to severe traumatic brain injury in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29626?source=see_link\">",
"     \"Concussion and mild traumatic brain injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40249?source=see_link\">",
"     \"Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Minor head trauma",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Children younger than two years of age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minor head trauma is generally defined separately in children younger than two years of age for the following reasons [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Clinical assessment is more difficult",
"     </li>",
"     <li>",
"      Infants with intracranial injuries are frequently asymptomatic",
"     </li>",
"     <li>",
"      Skull fractures may occur as the result of minor trauma",
"     </li>",
"     <li>",
"      Inflicted injury occurs more often",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Experts define minor head trauma in this age group as a history or physical signs of blunt trauma to the scalp, skull, or brain in an infant or child who is alert or awakens to voice or light touch [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Children two years of age and older",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definition of minor head trauma for children two years of age and older has often been based on the Glasgow Coma Scale (GCS). Some have defined minor head trauma as a GCS score of 15, whereas others have included children with scores &ge;13 (",
"    <a class=\"graphic graphic_table graphicRef59662 \" href=\"UTD.htm?2/58/2989\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. However, the rate of traumatic brain injury in children with a GCS of 13 is as high as 20 percent.",
"   </p>",
"   <p>",
"    Thus, for the purposes of this discussion, we define minor head trauma in previously healthy children two years of age and older as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Normal mental status at the initial examination",
"     </li>",
"     <li>",
"      No abnormal or focal findings on neurologic examination",
"     </li>",
"     <li>",
"      No physical evidence of skull fracture",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children who meet this definition of minor head trauma have a GCS score of 15.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Mild traumatic brain injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild traumatic brain injury (TBI) is generally associated with symptoms such as a brief loss of consciousness, disorientation, or vomiting. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Clinical features'",
"    </a>",
"    below.) Like minor head trauma, patients with mild TBI usually have GCS scores of 13 to 15, measured approximately 30 minutes after the injury. In comparison, patients with moderate TBI generally have initial GCS scores between 9 and 12, whereas those with severe injury have GCS scores &le;8 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Concussion is often used as a synonym for mild TBI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29626?source=see_link&amp;anchor=H2#H2\">",
"     \"Concussion and mild traumatic brain injury\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Concussion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concussion has been defined by the American Academy of Neurology as any traumatically induced disturbance of neurological function and mental state, occurring with or without actual loss of consciousness.",
"   </p>",
"   <p>",
"    Subsequent clinical manifestations following a mild concussion may be as subtle as headache or vomiting. Other more severely affected children may have significant but self-limited symptoms including loss of consciousness, amnesia, and altered mental status. The onset of impairment is rapid, but usually short-lived, and generally resolves spontaneously. The presence of an abnormality consistent with intracranial injury on CT scan precludes the diagnosis of a simple concussion. However, a CT is not necessary to make the diagnosis of concussion.",
"   </p>",
"   <p>",
"    A detailed discussion of the clinical features of concussion and the grading of concussive injury is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29626?source=see_link&amp;anchor=H5#H5\">",
"     \"Concussion and mild traumatic brain injury\", section on 'Clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29626?source=see_link&amp;anchor=H14#H14\">",
"     \"Concussion and mild traumatic brain injury\", section on 'Sequelae'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Head trauma occurs commonly in children. Among children 0 to 14 years of age, traumatic brain injury (TBI) accounted for approximately 435,000 emergency department visits and 37,000 hospitalizations annually between 1995 and 2001 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/6\">",
"     6",
"    </a>",
"    ]. In developed countries, TBI is the most common cause of death and disability in childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/7\">",
"     7",
"    </a>",
"    ]. Approximately 3000 children die each year of head injuries in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most children with head trauma are young, male, and have a mild injury. This was demonstrated in a large prospective series that described minor head trauma in children in the United Kingdom [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/10\">",
"     10",
"    </a>",
"    ]. Fifty-five percent of children were younger than five years of age, with 28 percent younger than two years of age. Boys accounted for 65 percent of patients, and 98 percent of children had Glasgow Coma Scale (GCS) scores of 15. Other series of children with head trauma have reported lower GCS scores, but many of these describe selected populations, such as children with head injury who had neuroimaging performed [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MECHANISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Falls are the most common mechanism of injury for children sustaining minor head trauma, followed by motor vehicle crashes, pedestrian and bicycle accidents, projectiles, assaults, sports-related trauma, and abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/10,13\">",
"     10,13",
"    </a>",
"    ]. These mechanisms cause isolated head trauma in the majority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infants sustain more falls and are at increased risk for inflicted injury. It is of utmost importance to identify children who have sustained an inflicted head injury, even if the injury is minor. Children who remain in the care of the alleged perpetrator are at significant risk for being injured again. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32985?source=see_link\">",
"     \"Child abuse: Epidemiology, mechanisms, and types of abusive head trauma in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20602?source=see_link\">",
"     \"Child abuse: Eye findings in children with abusive head trauma (AHT)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain injury can occur following a minor head trauma because rotational acceleration-deceleration of the head generates shearing forces that cause mechanical disruption of nerve fibers, resulting in diffuse axonal injury. This process has been described in association with severe brain injury and occurs in mild traumatic brain injury (TBI) as well. Whether or not this pattern of injury differs in the developing brain is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29626?source=see_link&amp;anchor=H4#H4\">",
"     \"Concussion and mild traumatic brain injury\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The type of mechanical forces applied to the brain may determine, to some extent, the nature of the resultant injury [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acceleration occurs when a moving object strikes a stationary head. Linear acceleration is considered the least injurious force and typically is associated with superficial contusions or in some cases, subdural hematomas.",
"     </li>",
"     <li>",
"      Deceleration results when a moving head strikes a stationary surface. Sudden deceleration is thought to be responsible for most severe brainstem injuries.",
"     </li>",
"     <li>",
"      Rotation of the brain occurs when the head is struck in an asymmetric manner or an infant is vigorously shaken. Rotational acceleration-deceleration can induce widespread injury.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mild TBI usually occurs with head trauma due to contact",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <span class=\"nowrap\">",
"     acceleration/deceleration",
"    </span>",
"    forces.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     INCIDENCE OF INTRACRANIAL INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The true incidence of intracranial injury following minor head trauma is unknown. Most studies providing incidence data are from selected populations in which children with moderate to severe injury are overrepresented (for example, including only children who have had computed tomography (CT) or primarily children with nontrivial trauma) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/11,12,17,18\">",
"     11,12,17,18",
"    </a>",
"    ]. Consequently, the risk of intracranial injury in these series may be overestimated.",
"   </p>",
"   <p>",
"    Estimates of the incidence of intracranial injury following head trauma from selected populations are summarized as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among children two years of age and older with minor head trauma and a normal neurologic examination, 3 to 7 percent may have an intracranial injury noted on CT scan [",
"      <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/11-13,17-19\">",
"       11-13,17-19",
"      </a>",
"      ]. Of the overall study populations, approximately 0.1 to 0.6 percent require surgical intervention [",
"      <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/17,20-22\">",
"       17,20-22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For children younger than two years with minor head trauma and a normal neurologic examination, approximately 3 to 10 percent have an intracranial injury [",
"      <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/11-13,17,23\">",
"       11-13,17,23",
"      </a>",
"      ]. Many of these younger children have no clinical symptoms of brain injury (19 to 48 percent), although most of these patients have scalp hematomas [",
"      <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/13,24,25\">",
"       13,24,25",
"      </a>",
"      ]. In a prospective series of infants under two years of age, 1 of 14 asymptomatic infants with intracranial injury required surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data from two European populations suggest that the incidence of intracranial injury after minor head trauma is much lower (0.6 to 1.2 percent). However, only 2 to 3 percent of patients in these studies underwent neuroimaging [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to reports of the incidence of intracranial injury, some studies that describe clinical features following minor head trauma only included children who underwent head CT. Consequently, these data also likely represent children whose injuries were more severe.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Common clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two large prospective observational studies have identified the following common features associated with minor head trauma in children [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/13,26\">",
"     13,26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Loss of consciousness &ndash;",
"      </strong>",
"      Loss of consciousness (LOC) occurred in approximately 5 percent of children &lt;2 years of age in both studies. In one study, up to 13 percent of children &ge;2 years of age had some degree of LOC [",
"      <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/13\">",
"       13",
"      </a>",
"      ]. Documented LOC, particularly for longer than a few seconds, was associated with a somewhat increased risk for clinically important traumatic brain injury [",
"      <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/13\">",
"       13",
"      </a>",
"      ]. However, the risk of TBI in the setting of brief isolated LOC without any other symptoms or signs of TBI are very low [",
"      <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Headache &ndash;",
"      </strong>",
"      Headache was a frequent complaint, occurring in up to 45 percent of children. In preverbal children, irritability may be an indication of discomfort, such as headache [",
"      <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/13,26\">",
"       13,26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Vomiting &ndash;",
"      </strong>",
"      At least one episode of vomiting was reported in approximately 14 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/13\">",
"       13",
"      </a>",
"      ]. Many children who vomit following head trauma do not have intracranial injury. In a case control study comparing children with mild head injury (as defined by discharge to home from the ED) with and without vomiting, predictors of vomiting included a personal history of vomiting, motion sickness, and headache associated with the injury [",
"      <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/28\">",
"       28",
"      </a>",
"      ]. Nevertheless, a history of any vomiting after head trauma increases the risk of TBI somewhat [",
"      <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among unselected populations of children with head trauma, immediate post-traumatic seizures occurred in &le;0.6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. In smaller, heterogeneous series, seizures have been reported in approximately 3 to 8 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/4,17,29\">",
"     4,17,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Skull fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skull fractures are not uncommon following minor head trauma in children, particularly in those younger than two years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/3,30\">",
"     3,30",
"    </a>",
"    ]. The vast majority of skull fractures are linear. Among children with linear skull fractures, 15 to 30 percent have associated intracranial injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/1,17,18,25,31,32\">",
"     1,17,18,25,31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most children with skull fractures will have overlying scalp hematomas, but most scalp hematomas in older children are not associated with skull fractures. In infants younger than the age of one year, increased scalp hematoma size and location in the parietal or temporal areas suggest a higher incidence of skull fracture. In one prospective series, no child with a frontal hematoma had an intracranial injury [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/30\">",
"     30",
"    </a>",
"    ]. Skull fractures in children are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13704?source=see_link\">",
"     \"Skull fractures in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Other clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient cortical defects, such as cortical blindness and acute confusional states, have been reported in association with minor head trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. These deficits are thought to be secondary to vascular hyperreactivity and may be trauma-induced, migraine-equivalent phenomena. There are case reports of stroke following mild head trauma in children [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of the evaluation of children with apparently minor head trauma is to identify those with traumatic brain injury (TBI) who may require immediate intervention (as with an epidural hematoma) or close follow-up (as with a concussion), while limiting unnecessary neuroimaging procedures. In addition, children who may have sustained an inflicted injury must be identified. The evaluation of nonaccidental injury is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32985?source=see_link\">",
"     \"Child abuse: Epidemiology, mechanisms, and types of abusive head trauma in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Features of the history and physical examination, along with selective neuroimaging, generally identify children who have sustained a brain injury with acute management implications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historical features that may suggest an increased risk of intracranial injury include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High-risk mechanism such as fall from a significant height, any mechanism involving a motor vehicle, penetrating injury, inflicted injury, or unknown mechanism (which may represent inflicted injury)",
"     </li>",
"     <li>",
"      Seizure, confusion, or loss of consciousness",
"     </li>",
"     <li>",
"      Significant headache",
"     </li>",
"     <li>",
"      Vomiting",
"     </li>",
"     <li>",
"      Preexisting conditions that place the child at risk for intracranial hemorrhage, which include arteriovenous malformation, or bleeding disorder",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vital signs and evidence of associated extracranial injury, such as neck or abdominal tenderness, should be noted. In addition, a neurological examination (including mental status) should be performed. The presence of the following specific findings is significant (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7367?source=see_link\">",
"     \"Classification of trauma in children\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Scalp abnormalities such as hematoma, tenderness, or depression",
"     </li>",
"     <li>",
"      In infants, bulging anterior fontanelle",
"     </li>",
"     <li>",
"      Abnormal mental status",
"     </li>",
"     <li>",
"      Focal neurologic abnormality",
"     </li>",
"     <li>",
"      Signs of basilar skull fracture (periorbital ecchymosis, Battle's sign, hemotympanum (",
"      <a class=\"graphic graphic_picture graphicRef62387 \" href=\"UTD.htm?31/17/32031\">",
"       picture 1",
"      </a>",
"      ), CSF otorrhea, or CSF rhinorrhea)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR NEUROIMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a general rule, children with head trauma who are at risk for intracranial injury should be initially imaged with computed tomography (CT). Head CT identifies essentially all children with intracranial injuries requiring acute intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/3\">",
"     3",
"    </a>",
"    ]. Plain radiography is of little or no added value if a head CT is performed.",
"   </p>",
"   <p>",
"    Skull radiographs may be indicated when the history of trauma is uncertain (eg, skeletal survey in the evaluation of suspected abuse), to rule out the presence of a foreign body, or, rarely, to screen for fractures in selected asymptomatic patients 3 to 24 months of age with concerning scalp hematomas. However, skull radiographs should only be performed if a radiologist with pediatric expertise is available to provide an interpretation because physicians with pediatric emergency expertise may have limited accuracy in correctly identifying skull fractures in young children [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/38\">",
"     38",
"    </a>",
"    ]. If a screening skull radiograph shows a fracture, then a head CT should be performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13704?source=see_link&amp;anchor=H15#H15\">",
"     \"Skull fractures in children\", section on 'Radiologic evaluation'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H11\">",
"     'Incidence of intracranial injury'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Among children with minor head trauma, the incidence of injuries that require neurosurgical intervention is very low. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Incidence of intracranial injury'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Nevertheless, in the United States, the use of CT for the evaluation of children with head trauma has been increasing. This was demonstrated in a report of a cross-sectional analysis describing children with head trauma identified from a national database of hospital emergency department and outpatient department visits [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/39\">",
"     39",
"    </a>",
"    ]. The use of CT increased from 13 percent to 22 percent from 1995 to 2003, with a peak of 29 percent in 2000.",
"   </p>",
"   <p>",
"    Since 2003, two large prospective cohort studies in pediatric referral emergency departments in the United States and Canada found that 35 to 53 percent of children with minor head trauma underwent head CT [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/13,22\">",
"     13,22",
"    </a>",
"    ]. Children evaluated for closed head injury in US general emergency departments are about twice as likely to have head CTs performed as those seen in a pediatric hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The decision to obtain neuroimaging for children with minor head trauma must balance the importance of identifying significant, but rare, injuries with the risks of CT. The estimated lifetime risk of cancer mortality from a head CT is substantially higher for children than for adults because of a longer subsequent lifetime and the greater sensitivity of some developing organs to radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/41-46\">",
"     41-46",
"    </a>",
"    ]. In addition, some children may require sedation in order to obtain an adequate study. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23178?source=see_link&amp;anchor=H9#H9\">",
"     \"Approach to neuroimaging in children\", section on 'Radiation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=see_link&amp;anchor=H33#H33\">",
"     \"Procedural sedation in children outside of the operating room\", section on 'Adverse outcomes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Predictors of intracranial injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;No single clinical feature reliably predicts children with minor head trauma who have an intracranial injury and therefore should receive neuroimaging.",
"   </p>",
"   <p>",
"    Observational reports from selected populations have consistently described skull fracture, focal neurologic examination, and depressed mental status as significant predictors of children who are at high risk for intracranial injury [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/19,26,27,47-49\">",
"     19,26,27,47-49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Variable significance has been reported for seizures, loss of consciousness, amnesia, vomiting, age less than two years, trauma mechanism (eg, bicycle-related injury), scalp bruise or swelling in children &lt;1 year of age, and headache [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/19,27,47-51\">",
"     19,27,47-51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A multicenter, prospective observational study has derived and validated prediction rules for children at very low risk for clinically important traumatic brain injuries (ciTBI) in a cohort of 42,412 children younger than 18 years of age who had a Glasgow coma score of 14 to 15 and were evaluated within 24 hours of head trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/13\">",
"     13",
"    </a>",
"    ]. The definition of ciTBI included neurosurgery, endotracheal intubation for more than 24 hours, and hospitalization for more than two nights (",
"    <a class=\"graphic graphic_table graphicRef58477 \" href=\"UTD.htm?15/5/15452\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the validation group of 2216 children younger than two years of age, 25 had a ciTBI. The rule had a sensitivity of 100 percent (95% CI 86-100), a specificity of 54 percent (95% CI 53-55), and a negative predictive value of 100 percent (95% CI 99.7-100). The risk of ciTBI was 0.02 percent in children with none of the six clinical predictors present.",
"     </li>",
"     <li>",
"      In the validation group of 6411 children two years of age or older, 63 had a ciTBI. The rule had a sensitivity of 97 percent (95% CI 89-99.6), a specificity of 60 percent (95% CI 58.6-61), and a negative predictive value of 99.9 percent (95% CI 99.8-99.9). Two children with ciTBI were classified as low risk. Neither required neurosurgical intervention. The risk of ciTBI in children with none of the six clinical predictors present was less than 0.05 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Head CT was obtained in 14,969 patients (35 percent). Twenty-five percent of children younger than two years of age (N = 835) and 20 percent of children 2 to 18 years of age (N = 2438) had a head CT despite having a very low risk for ciTBI based on the prediction rule. These findings, when combined with evidence from prior observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/49,52\">",
"     49,52",
"    </a>",
"    ], suggest that the use of low-risk criteria and judicious observation of patients in lieu of head CT can allow the clinician to avoid head CT in a significant number of children undergoing evaluation for minor head trauma without missing clinically important intracranial injury. Furthermore, this decision rule is clear and relatively easy to implement. As an example, in an implementation study of this decision rule in 356 children with minor head injury (46 percent under two years of age), adherence to the rule was 94 percent and provider satisfaction was high [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/53\">",
"     53",
"    </a>",
"    ]. Although the rate of CT was not significantly different before and after implementation of the rule in this study, the baseline rate for head CT was already low (7 percent). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Children younger than two years",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large, multicenter observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/14,26,49\">",
"     14,26,49",
"    </a>",
"    ] support guidelines for evaluation and management that were proposed by expert consensus [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/2\">",
"     2",
"    </a>",
"    ]. These strategies consider high, intermediate, and low-risk criteria for intracranial injury:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Perform imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants and children younger than two years of age with high risk for intracranial injury or with suspected skull fracture should have head computed tomography (CT) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/2,13,54\">",
"     2,13,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High-risk signs or symptoms include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Focal neurologic findings",
"     </li>",
"     <li>",
"      Acute skull fracture, including depressed or basilar fracture",
"     </li>",
"     <li>",
"      Depressed mental status",
"     </li>",
"     <li>",
"      Irritability",
"     </li>",
"     <li>",
"      Bulging fontanel",
"     </li>",
"     <li>",
"      Persistent vomiting",
"     </li>",
"     <li>",
"      Seizure",
"     </li>",
"     <li>",
"      Definite loss of consciousness (especially more than a few seconds and associated with a high-risk mechanism of injury)",
"     </li>",
"     <li>",
"      Suspicion of child abuse",
"     </li>",
"     <li>",
"      Underlying condition predisposing to intracranial injury (see",
"      <a class=\"local\" href=\"#H18\">",
"       'History'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of clinically important traumatic brain injury is 4 percent or higher for patients with one or more of these findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Observe or perform imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intermediate-risk patients may be managed with close observation for four to six hours after the injury (with imaging obtained for any worsening condition during this period), or they may be evaluated immediately by head CT.",
"   </p>",
"   <p>",
"    Intermediate-risk signs or symptoms include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Vomiting",
"     </li>",
"     <li>",
"      Loss of consciousness that is uncertain or very brief (less than a few seconds)",
"     </li>",
"     <li>",
"      History of lethargy or irritability, now resolved",
"     </li>",
"     <li>",
"      Behavioral change reported by caregiver",
"     </li>",
"     <li>",
"      Injury caused by high-risk mechanism of injury (eg, fall more than three to four feet, patient ejection, death of a passenger, rollover, high-impact head injury)",
"     </li>",
"     <li>",
"      Scalp hematoma (particularly nonfrontal)",
"     </li>",
"     <li>",
"      Skull fracture more than 24 hours old (nonacute)",
"     </li>",
"     <li>",
"      Unwitnessed trauma that may be significant",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of clinically important traumatic brain injury is approximately 1 percent for a child with at least one of these criteria and 0.3 percent if the sole criteria is a high-risk mechanism for injury [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/13,55\">",
"     13,55",
"    </a>",
"    ]. Multiple or worsening symptoms or signs likely put the child at greater risk than an isolated finding [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/13,14,19\">",
"     13,14,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Performing a head CT is suggested for intermediate-risk children under the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Presence of more than one of the intermediate-risk factors noted above",
"     </li>",
"     <li>",
"      Vomiting that is delayed by several hours after injury or occurs multiple times",
"     </li>",
"     <li>",
"      Large nonfrontal scalp hematomas, especially in children younger than 12 months [",
"      <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/30\">",
"       30",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Infants less than three months old with nontrivial trauma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If immediate CT is deferred for these patients, we suggest observation for four to six hours to ensure no progression of clinical findings that warrant CT.",
"   </p>",
"   <p>",
"    Skull radiographs may occasionally be useful to screen for fracture and avoid the risk of radiation and sedation from CT in selected asymptomatic patients 3 to 24 months of age with concerning scalp hematomas [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/54\">",
"     54",
"    </a>",
"    ]. However, skull radiographs should only be performed if a radiologist with pediatric expertise is available to provide an interpretation because physicians with pediatric emergency expertise may have limited accuracy in correctly identifying skull fractures in young children [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/38\">",
"     38",
"    </a>",
"    ]. If a screening skull radiograph shows a fracture, then a head CT should be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Do not perform imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging studies should be avoided in children &lt;2 years of age at very low risk for brain injury. These patients should have a normal neurologic examination (including a normal fontanel), no history of seizure, and no persistent vomiting. The clinician should also have no suspicion for abuse. Validated criteria include [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Normal mental status",
"     </li>",
"     <li>",
"      No parietal, occipital or temporal scalp hematoma",
"     </li>",
"     <li>",
"      No loss of consciousness",
"     </li>",
"     <li>",
"      No evidence of skull fracture",
"     </li>",
"     <li>",
"      Normal behavior according to the routine caregiver",
"     </li>",
"     <li>",
"      No high-risk mechanism of injury (severe mechanisms: fall &gt;0.9 m (3 feet); head struck by high impact object; motor vehicle collision with patient ejection, death of another passenger, or rollover; pedestrian or bicyclist without helmet struck by a motorized vehicle)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk for clinically important traumatic brain injury is less than 0.02 percent in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Children two years of age and older",
"    </span>",
"    &nbsp;&mdash;&nbsp;Criteria to guide decisions about neuroimaging in children two years of age and older are derived from several large multicenter observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/13,19,26\">",
"     13,19,26",
"    </a>",
"    ] and a metaanalysis of observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Perform neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children &ge;2 years of age with the following signs and symptoms appear to be at the most significant risk for intracranial injury and should have computed tomography of the head performed [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/13,19,26,47\">",
"     13,19,26,47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Focal neurologic findings",
"     </li>",
"     <li>",
"      Skull fracture, especially findings of basilar skull fracture",
"     </li>",
"     <li>",
"      Seizure",
"     </li>",
"     <li>",
"      Altered mental status (eg, agitation, lethargy, repetitive questioning, or slow response to verbal questioning)",
"     </li>",
"     <li>",
"      Prolonged loss of consciousness",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Observe or perform neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;For children with signs and symptoms that have been variably associated with intracranial injury, close observation for four to six hours after the injury (with imaging obtained for any worsening symptoms or concerns during this period) is an alternative to immediate computed tomography of the head. The clinician should have a lower threshold for imaging for severe, persistent, worsening, or multiple clinical findings. These signs and symptoms include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Vomiting",
"     </li>",
"     <li>",
"      Headache",
"     </li>",
"     <li>",
"      Questionable or brief loss of consciousness",
"     </li>",
"     <li>",
"      Injury caused by high-risk mechanism of injury",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of clinically important traumatic brain injury is approximately 1 percent in patients with at least one of these criteria and 0.6 percent if the sole criteria is a high-risk mechanism for injury [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/13,55\">",
"     13,55",
"    </a>",
"    ]. Multiple or worsening symptoms or signs likely puts the child at greater risk than an isolated finding [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/13,14,19\">",
"     13,14,19",
"    </a>",
"    ]. Evidence suggests that observation of patients with these signs and symptoms may decrease the utilization of head CT without missing clinically important traumatic brain injury. As an example, in a multicenter, prospective observational study, children who were observed had a lower rate of head CT use than those who were not (31 versus 35 percent, respectively, difference -4 percent [95% CI -5 to -3 percent]) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/56\">",
"     56",
"    </a>",
"    ]. The observed patients had a similar rate of clinically important traumatic brain injury (0.8 versus 0.9 percent). In this study, most observed children were older than two years of age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Do not perform neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging studies should be avoided in children &ge;2 years of age at very low risk for clinically important brain injury. These patients should have a normal neurologic examination, no physical evidence suggesting a skull fracture, and no preexisting condition that might increase the risk of intracranial hemorrhage (eg, bleeding disorder) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/57\">",
"     57",
"    </a>",
"    ]. Validated criteria include [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Normal mental status",
"     </li>",
"     <li>",
"      No loss of consciousness",
"     </li>",
"     <li>",
"      No vomiting",
"     </li>",
"     <li>",
"      No signs of basilar skull fracture",
"     </li>",
"     <li>",
"      No severe headache",
"     </li>",
"     <li>",
"      No high-risk mechanism of injury (severe mechanisms: fall &gt;1.5 m (5 feet); head struck by high impact object; motor vehicle collision with patient ejection, death of another passenger, or rollover; pedestrian or bicyclist without a helmet struck by a motorized vehicle)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk for clinically important traumatic brain injury is less than 0.05 percent in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues involved in the management of children with minor head trauma include need for neurosurgical consultation, disposition, and, for the injured athlete, return to play.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Neurosurgical consultation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurosurgical consultation should be obtained in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Brain injury detected by computed tomography (CT)",
"     </li>",
"     <li>",
"      Depressed, basilar, or widely diastatic skull fracture",
"     </li>",
"     <li>",
"      Deteriorating clinical condition",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Disposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any child who has had a minor head trauma requires observation, whether at home, in the clinician's office, or in the emergency department. Observation in the hospital is indicated in some circumstances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Home management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Health care providers are frequently contacted by telephone after a child has sustained minor head trauma. Observation at home without in-person evaluation is reasonable under the following conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Normal mental status and at a baseline level of function",
"     </li>",
"     <li>",
"      Low-risk mechanism of injury",
"     </li>",
"     <li>",
"      No concern for inflicted injury",
"     </li>",
"     <li>",
"      No loss of consciousness or seizure",
"     </li>",
"     <li>",
"      No other apparent injuries",
"     </li>",
"     <li>",
"      No vomiting or only one episode of vomiting occurring shortly after injury",
"     </li>",
"     <li>",
"      No significant headache",
"     </li>",
"     <li>",
"      For the infants &lt;1 year of age, trivial injury without significant nonfrontal hematoma",
"     </li>",
"     <li>",
"      No underlying conditions predisposing to intracranial injury",
"     </li>",
"     <li>",
"      Reliable caretakers who are able to seek care, if indicated",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children who have sustained head trauma that meets these criteria may resume normal activity. It is not necessary to awaken them from sleep for monitoring. Caretakers should be instructed to seek medical advice for the following indications:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Persistent or worsening headaches",
"     </li>",
"     <li>",
"      Vomiting after the initial injury",
"     </li>",
"     <li>",
"      Change in mental status or behavior",
"     </li>",
"     <li>",
"      Unsteady gait or",
"      <span class=\"nowrap\">",
"       clumsiness/incoordination",
"      </span>",
"     </li>",
"     <li>",
"      Seizure",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Office or emergency department",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most children who have had isolated minor head trauma, including those who have had computed tomography (CT) of the head performed that is normal, can be safely discharged following evaluation and a brief period of observation.",
"   </p>",
"   <p>",
"    The following conditions should be met prior to discharge:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is no suspicion of inflicted injury.",
"     </li>",
"     <li>",
"      The child is easily aroused with light touch and has a normal neurologic examination.",
"     </li>",
"     <li>",
"      The child has returned to baseline level of function and tolerated oral fluids, if there has been vomiting.",
"     </li>",
"     <li>",
"      Caretakers are capable of reliably observing the child and can return for care if indicated.",
"     </li>",
"     <li>",
"      Specific instructions have been given regarding the level of observation required, indications for seeking care, and follow-up.",
"     </li>",
"     <li>",
"      There are no extracranial injuries requiring admission.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Evidence supporting this approach is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An observational study of 17,962 children evaluated in an emergency department for uncomplicated minor head injuries found that the incidences of delayed diagnosis of an intracranial injury were 0.14 and 0.57 cases per 100,000 children per year for patients with and without worsening level of consciousness, respectively. Not all of the children in this study underwent head CT [",
"      <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A multicenter observational study analyzed 13,543 children who were evaluated in children&rsquo;s hospital emergency departments for isolated minor head trauma (Glasgow coma scale 14 or 15) and who had normal cranial computed tomography (CT) scan results [",
"      <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/59\">",
"       59",
"      </a>",
"      ]. Repeat neuroimaging (CT or magnetic resonance imaging) was performed in 2 percent of 11,058 discharged patients and 6 percent of admitted patients. Of these, 0.05 and 0.6 percent of discharged patients and admitted patients, respectively, subsequently had positive findings upon repeat head CT. No patient in either group required neurosurgical intervention. Successful telephone or mail follow-up occurred in 79 percent of the discharged patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, children with minor head trauma and a normal level of consciousness at emergency department discharge are unlikely to have intracranial abnormalities upon repeated neuroimaging or to require neurosurgical intervention, especially if they have a normal head CT at initial evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Discharge instructions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Caretakers of children who have been evaluated for minor head trauma should be given explicit and understandable instructions for monitoring, when to seek medical help, and when to return for follow-up. It is not necessary to awaken most children. Whether it is important to awaken some children to identify the very few who may be experiencing a change in neurologic condition is uncertain, since no data are currently available that address this question. Those who had a concerning mechanism or prolonged symptoms may be awakened from sleep every four or more hours. The child should be able to recognize his or her surroundings and appear alert to the caretaker. Follow-up within 24 hours, at least by telephone, should be arranged for all children who are discharged following a head injury.",
"   </p>",
"   <p>",
"    Immediate medical attention is required when the following conditions are noted:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inability to awaken the child as instructed",
"     </li>",
"     <li>",
"      Persistent or worsening headache",
"     </li>",
"     <li>",
"      Continued vomiting or vomiting that",
"      <span class=\"nowrap\">",
"       begins/continues",
"      </span>",
"      four to six hours after injury",
"     </li>",
"     <li>",
"      Change in mental status or behavior",
"     </li>",
"     <li>",
"      Unsteady gait or",
"      <span class=\"nowrap\">",
"       clumsiness/incoordination",
"      </span>",
"     </li>",
"     <li>",
"      Seizure",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Hospital admission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hospital admission is generally warranted under the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Brain injury or depressed or basilar skull fracture, in consultation with a neurosurgeon",
"     </li>",
"     <li>",
"      Persistent, significant alteration in mental status despite normal head CT",
"     </li>",
"     <li>",
"      Unremitting vomiting",
"     </li>",
"     <li>",
"      Suspected inflicted injury",
"     </li>",
"     <li>",
"      Extracranial injury requiring admission",
"     </li>",
"     <li>",
"      Caretakers who are unreliable or unable to return for care",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Post-traumatic seizure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who have had a brief immediate post-traumatic seizure following minor head trauma and have a normal head CT may not require admission to the hospital. In two observational cohorts describing similar patients, no further seizure activity or neurologic sequelae were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/29,60\">",
"     29,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest that children who have had a brief seizure and who have a normal neurologic examination and head CT be observed for several hours in the office or emergency department. They may be discharged once they meet the criteria described above. (See",
"    <a class=\"local\" href=\"#H34\">",
"     'Office or emergency department'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    At home, children may be awakened from sleep every four or more hours for monitoring purposes and should have follow-up again in 24 hours, although there is no data to guide specific follow-up recommendations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Return to play",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children and adolescents who have sustained a concussion may be at greater risk for second impact syndrome than older athletes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H40\">",
"     'Second impact syndrome'",
"    </a>",
"    below.) In addition, the cumulative effect of mild, repetitive brain injury on the developing brain is uncertain. Conservative guidelines for when a young athlete may return to play are therefore recommended.",
"   </p>",
"   <p>",
"    Any child who has had loss of consciousness or symptoms of concussion lasting more than 15 minutes as the result of minor head trauma should",
"    <strong>",
"     not",
"    </strong>",
"    participate in sports until asymptomatic for at least one week. Return to play guidelines are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29626?source=see_link&amp;anchor=H14#H14\">",
"     \"Concussion and mild traumatic brain injury\", section on 'Sequelae'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     SEQUELAE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outcome generally is good for children with minor head trauma with no apparent intracranial injury [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/57,63\">",
"     57,63",
"    </a>",
"    ]. Short and long-term sequelae that may have implications for children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29626?source=see_link&amp;anchor=H14#H14\">",
"     \"Concussion and mild traumatic brain injury\", section on 'Sequelae'",
"    </a>",
"    .) Second impact syndrome and postconcussion syndrome are of particular interest.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Second impact syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The second impact syndrome refers to diffuse cerebral swelling that follows a second concussion, which occurs while an athlete is still symptomatic from an earlier concussion. This rare, but often fatal, complication of mild head trauma can usually be prevented by careful assessment before allowing children to resume participation in sports followed by a gradual return to activity once they are asymptomatic. Second impact syndrome and return to play instructions are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29626?source=see_link&amp;anchor=H14#H14\">",
"     \"Concussion and mild traumatic brain injury\", section on 'Sequelae'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Postconcussion syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The postconcussion syndrome (PCS) is a symptom complex that occurs following mild traumatic brain injury (TBI) that may include headache, dizziness, neuropsychiatric symptoms, and cognitive impairment. The incidence of postconcussion syndrome among children is uncertain, but it is probably lower than in adults. Children who have symptoms that persist beyond several weeks may be referred for evaluation. Postconcussion syndrome is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33929?source=see_link\">",
"     \"Postconcussion syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Short-term functional morbidity, perhaps related to parental concern and social factors, has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/64\">",
"     64",
"    </a>",
"    ]. These findings emphasize the importance of primary care follow-up for children and families after apparently minor head trauma.",
"   </p>",
"   <p>",
"    Long-term cognitive and behavioral difficulties have been reported in studies of small populations of children following head injuries of varying severity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/65-71\">",
"     65-71",
"    </a>",
"    ]. Cognitive dysfunction among young adults who had mild head trauma in childhood has been reported as well [",
"    <a class=\"abstract\" href=\"UTD.htm?12/38/12906/abstract/72\">",
"     72",
"    </a>",
"    ]. Predicting factors that identify children destined to have these neurocognitive sequelae after minor head trauma has been poorly studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/45/40658?source=see_link\">",
"       \"Patient information: Head injury in children and adolescents (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/12/22722?source=see_link\">",
"       \"Patient information: Concussion (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/24/34178?source=see_link\">",
"       \"Patient information: Skull and facial fractures (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/47/8947?source=see_link\">",
"       \"Patient information: Closed head injury (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/44/14020?source=see_link\">",
"       \"Patient information: Head injury in children and adolescents (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minor head trauma occurs commonly in children. Although associated intracranial injury occurs in a small percentage of those children who have a normal neurologic examination at presentation, it must be recognized in order to prevent deterioration and subsequent morbidity or mortality. In addition, inflicted injury must also be identified because it often results in serious intracranial injury and carries a significant risk of recurrence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32985?source=see_link\">",
"     \"Child abuse: Epidemiology, mechanisms, and types of abusive head trauma in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Predictors of intracranial injury after minor head trauma include (see",
"    <a class=\"local\" href=\"#H21\">",
"     'Predictors of intracranial injury'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prolonged LOC",
"     </li>",
"     <li>",
"      Amnesia",
"     </li>",
"     <li>",
"      Vomiting that is delayed by several hours after injury or occurs more than once",
"     </li>",
"     <li>",
"      Seizure",
"     </li>",
"     <li>",
"      Severe headache",
"     </li>",
"     <li>",
"      Suspicion of inflicted head injury",
"     </li>",
"     <li>",
"      GCS score &lt;15",
"     </li>",
"     <li>",
"      Signs of a depressed or basilar skull fracture or bulging fontanel",
"     </li>",
"     <li>",
"      Focal neurologic examination",
"     </li>",
"     <li>",
"      Nonfrontal scalp hematoma for children &lt;2 years of age",
"     </li>",
"     <li>",
"      Significant mechanism of injury",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Indications for neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroimaging with computed tomography (CT) reliably identifies significant intracranial injury. However, there is a small risk of later malignancy with exposure to ionizing radiation. In addition, some children may require sedation in order to perform the study. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Indications for neuroimaging'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h3\">",
"     Infants and children younger than two years of age",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend that infants and children younger than two years of age have head computed tomography (CT) in the following situations (see",
"    <a class=\"local\" href=\"#H23\">",
"     'Perform imaging'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Focal neurologic findings",
"     </li>",
"     <li>",
"      Acute skull fracture, including depressed or basilar fracture",
"     </li>",
"     <li>",
"      Depressed mental status",
"     </li>",
"     <li>",
"      Irritability",
"     </li>",
"     <li>",
"      Bulging fontanel",
"     </li>",
"     <li>",
"      Persistent vomiting",
"     </li>",
"     <li>",
"      Seizure",
"     </li>",
"     <li>",
"      Definite loss of consciousness (especially more than a few seconds and associated with a high-risk mechanism of injury)",
"     </li>",
"     <li>",
"      Suspicion of child abuse",
"     </li>",
"     <li>",
"      Underlying condition predisposing to intracranial injury (see",
"      <a class=\"local\" href=\"#H18\">",
"       'History'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest that infants and children younger than two years of age with the followings indications undergo a head CT (see",
"      <a class=\"local\" href=\"#H24\">",
"       'Observe or perform imaging'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Large nonfrontal scalp hematomas, especially in children younger than 12 months",
"     </li>",
"     <li>",
"      Infants less than three months old with nontrivial trauma",
"     </li>",
"     <li>",
"      Vomiting that is delayed by several hours after injury or occurs repeatedly",
"     </li>",
"     <li>",
"      Presence of more than one of the intermediate-risk factors noted below",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If immediate CT is deferred for patients with these intermediate findings, we suggest observation for four to six hours to ensure no progression of clinical findings that warrant CT.",
"     </li>",
"     <li>",
"      Skull radiographs may be used to screen for a fracture in asymptomatic patients 3 to 24 months of age with concerning scalp hematomas if a radiologist with pediatric expertise is available to provide an emergent reading: CT is indicated if a fracture is present. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Observe or perform imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that infants and children younger than two years of age with any one of the following intermediate-risk criteria may either be observed for four to six hours or have an immediate head CT (see",
"      <a class=\"local\" href=\"#H24\">",
"       'Observe or perform imaging'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Vomiting that occurs only once soon after injury",
"     </li>",
"     <li>",
"      Loss of consciousness that is uncertain or very brief (less than a few seconds)",
"     </li>",
"     <li>",
"      History of lethargy or irritability, now resolved",
"     </li>",
"     <li>",
"      Behavioral change reported by caregiver",
"     </li>",
"     <li>",
"      Skull fracture more than 24 hours old (nonacute)",
"     </li>",
"     <li>",
"      Injury caused by high-risk mechanism of injury (eg, fall more than three to four feet, patient ejection, death of a passenger, rollover, high impact head injury)",
"     </li>",
"     <li>",
"      Unwitnessed trauma that may be significant",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that infants and children younger than two years of age with the following findings",
"      <strong>",
"       not",
"      </strong>",
"      undergo head CT:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Normal mental status",
"     </li>",
"     <li>",
"      No nonfrontal scalp hematoma",
"     </li>",
"     <li>",
"      No loss of consciousness",
"     </li>",
"     <li>",
"      No evidence of skull fracture",
"     </li>",
"     <li>",
"      Normal behavior according to the routine caregiver",
"     </li>",
"     <li>",
"      No high-risk mechanism of injury (severe mechanisms: fall &gt;0.9 m (3 feet); head struck by high impact object; motor vehicle collision with patient ejection, death of another passenger, or rollover; pedestrian or bicyclist without helmet struck by a motorized vehicle)",
"      <br/>",
"      <br/>",
"      These patients should also have a normal neurologic examination (including a normal fontanel), no history of seizure, and no persistent vomiting. The clinician should also have no suspicion for abuse. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Do not perform imaging'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h3\">",
"     Children two years of age and older",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend that children two years of age and older have head computed tomography (CT) in the following situations (see",
"    <a class=\"local\" href=\"#H27\">",
"     'Perform neuroimaging'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Focal neurologic findings",
"     </li>",
"     <li>",
"      Skull fracture, especially findings of basilar skull fracture",
"     </li>",
"     <li>",
"      Seizure",
"     </li>",
"     <li>",
"      Prolonged loss of consciousness",
"     </li>",
"     <li>",
"      Altered mental status (eg, agitation, lethargy, repetitive questioning, or slow response to verbal questioning)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest that children with the following signs and symptoms either be closely observed for four to six hours after the injury (with imaging obtained for any worsening symptoms or concerns during this period) or have immediate head CT:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Vomiting",
"     </li>",
"     <li>",
"      Headache",
"     </li>",
"     <li>",
"      Questionable or brief loss of consciousness with no other signs or symptoms",
"     </li>",
"     <li>",
"      Injury caused by high-risk mechanism of injury (severe mechanisms: fall &gt;1.5 m (5 feet) in child age two years and older; head struck by high impact object; motor vehicle collision with patient ejection, death of another passenger, or rollover; pedestrian or bicyclist without a helmet struck by a motorized vehicle)",
"      <br/>",
"      <br/>",
"      The clinician should have a lower threshold for imaging patients with severe, persistent, or multiple clinical findings.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that neurologically normal children two years of age and older who meet the following criteria",
"      <strong>",
"       not",
"      </strong>",
"      undergo head CT:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Normal mental status",
"     </li>",
"     <li>",
"      No loss of consciousness",
"     </li>",
"     <li>",
"      No vomiting",
"     </li>",
"     <li>",
"      No signs of basilar skull fracture",
"     </li>",
"     <li>",
"      No severe headache",
"     </li>",
"     <li>",
"      No high-risk mechanism of injury (severe mechanisms: fall &gt;1.5 m (5 feet) in child age two years and older; head struck by high impact object; motor vehicle collision with patient ejection, death of another passenger, or rollover; pedestrian or bicyclist without a helmet struck by a motorized vehicle)",
"      <br/>",
"      <br/>",
"      This recommendation places a high value on the potential harm of radiation exposure from head computed tomography and recognizes the very low chance of clinically important traumatic brain injury in such patients. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Do not perform neuroimaging'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h2\">",
"     Disposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who have sustained minor head trauma may be observed at home, in the office, or in the emergency department, depending on their clinical condition. (See",
"    <a class=\"local\" href=\"#H33\">",
"     'Home management'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H34\">",
"     'Office or emergency department'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that children with the following indications be admitted to the hospital (see",
"      <a class=\"local\" href=\"#H36\">",
"       'Hospital admission'",
"      </a>",
"      above)&nbsp;(",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Brain injury or depressed or basilar skull fracture in consultation with a neurosurgeon",
"     </li>",
"     <li>",
"      Persistent, significant alteration in mental status despite normal head CT",
"     </li>",
"     <li>",
"      Suspected inflicted injury",
"     </li>",
"     <li>",
"      Unremitting vomiting",
"     </li>",
"     <li>",
"      Caretakers who are unreliable",
"     </li>",
"     <li>",
"      Caretakers who are unable to follow-up or return for care",
"     </li>",
"     <li>",
"      Extracranial injury requiring admission",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Careful discharge instructions regarding monitoring, indications to seek care, and follow-up must be given to a reliable caretaker. (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Discharge instructions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children who have sustained a concussion must be carefully evaluated to determine when it is safe for them to return to sports.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/1\">",
"      Duhaime AC, Alario AJ, Lewander WJ, et al. Head injury in very young children: mechanisms, injury types, and ophthalmologic findings in 100 hospitalized patients younger than 2 years of age. Pediatrics 1992; 90:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/2\">",
"      Schutzman SA, Barnes P, Duhaime AC, et al. Evaluation and management of children younger than two years old with apparently minor head trauma: proposed guidelines. Pediatrics 2001; 107:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/3\">",
"      Schutzman SA, Greenes DS. Pediatric minor head trauma. Ann Emerg Med 2001; 37:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/4\">",
"      Davis RL, Mullen N, Makela M, et al. Cranial computed tomography scans in children after minimal head injury with loss of consciousness. Ann Emerg Med 1994; 24:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/5\">",
"      Marcin JP, Pollack MM. Triage scoring systems, severity of illness measures, and mortality prediction models in pediatric trauma. Crit Care Med 2002; 30:S457.",
"     </a>",
"    </li>",
"    <li>",
"     Langlois JA, Rutland-Brown W, Thomas KE. Traumatic Brain Injury in the United States: Emergency Department Visits, Hospitalizations, and Deaths, Centers for Disease Control and Prevention, National Center for Injury Prevention and Control, Atlanta 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/7\">",
"      Luerssen TG, Klauber MR, Marshall LF. Outcome from head injury related to patient's age. A longitudinal prospective study of adult and pediatric head injury. J Neurosurg 1988; 68:409.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. 2000 National Hospital Ambulatory Medical Care Survey, Emergency Department File 2002, National Center for Health Statistics, Hyattsville, MD (2002) Vital Health Stat Series 13, No. 33.",
"    </li>",
"    <li>",
"     National Center for Injury Prevention and Control. Traumatic Brain Injury in the United States: Assessing Outcomes in Children, Centers for Disease Control and Prevention, Atlanta 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/10\">",
"      Dunning J, Daly JP, Malhotra R, et al. The implications of NICE guidelines on the management of children presenting with head injury. Arch Dis Child 2004; 89:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/11\">",
"      Dietrich AM, Bowman MJ, Ginn-Pease ME, et al. Pediatric head injuries: can clinical factors reliably predict an abnormality on computed tomography? Ann Emerg Med 1993; 22:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/12\">",
"      Quayle KS, Jaffe DM, Kuppermann N, et al. Diagnostic testing for acute head injury in children: when are head computed tomography and skull radiographs indicated? Pediatrics 1997; 99:E11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/13\">",
"      Kuppermann N, Holmes JF, Dayan PS, et al. Identification of children at very low risk of clinically-important brain injuries after head trauma: a prospective cohort study. Lancet 2009; 374:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/14\">",
"      Medana IM, Esiri MM. Axonal damage: a key predictor of outcome in human CNS diseases. Brain 2003; 126:515.",
"     </a>",
"    </li>",
"    <li>",
"     Rosman, NP. Acute head trauma. In: Oski's Pediatrics: Principles and Practice, 3rd ed, McMillan, JA, DeAngelis, CD, Feigin, RD, Warshaw, J (Eds), Lippincott, Williams and Wilkins, Philadelphia 1999. p.603.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/16\">",
"      Duhaime AC, Christian CW, Rorke LB, Zimmerman RA. Nonaccidental head injury in infants--the \"shaken-baby syndrome\". N Engl J Med 1998; 338:1822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/17\">",
"      Schunk JE, Rodgerson JD, Woodward GA. The utility of head computed tomographic scanning in pediatric patients with normal neurologic examination in the emergency department. Pediatr Emerg Care 1996; 12:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/18\">",
"      Hahn YS, McLone DG. Risk factors in the outcome of children with minor head injury. Pediatr Neurosurg 1993; 19:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/19\">",
"      Palchak MJ, Holmes JF, Vance CW, et al. A decision rule for identifying children at low risk for brain injuries after blunt head trauma. Ann Emerg Med 2003; 42:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/20\">",
"      Rosenthal BW, Bergman I. Intracranial injury after moderate head trauma in children. J Pediatr 1989; 115:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/21\">",
"      Dacey RG Jr, Alves WM, Rimel RW, et al. Neurosurgical complications after apparently minor head injury. Assessment of risk in a series of 610 patients. J Neurosurg 1986; 65:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/22\">",
"      Osmond MH, Klassen TP, Wells GA, et al. CATCH: a clinical decision rule for the use of computed tomography in children with minor head injury. CMAJ 2010; 182:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/23\">",
"      Gruskin KD, Schutzman SA. Head trauma in children younger than 2 years: are there predictors for complications? Arch Pediatr Adolesc Med 1999; 153:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/24\">",
"      Greenes DS, Schutzman SA. Occult intracranial injury in infants. Ann Emerg Med 1998; 32:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/25\">",
"      Greenes DS, Schutzman SA. Clinical indicators of intracranial injury in head-injured infants. Pediatrics 1999; 104:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/26\">",
"      Dunning J, Daly JP, Lomas JP, et al. Derivation of the children's head injury algorithm for the prediction of important clinical events decision rule for head injury in children. Arch Dis Child 2006; 91:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/27\">",
"      Da Dalt L, Marchi AG, Laudizi L, et al. Predictors of intracranial injuries in children after blunt head trauma. Eur J Pediatr 2006; 165:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/28\">",
"      Da Dalt L, Andreola B, Facchin P, et al. Characteristics of children with vomiting after minor head trauma: a case-control study. J Pediatr 2007; 150:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/29\">",
"      Holmes JF, Palchak MJ, Conklin MJ, Kuppermann N. Do children require hospitalization after immediate posttraumatic seizures? Ann Emerg Med 2004; 43:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/30\">",
"      Greenes DS, Schutzman SA. Clinical significance of scalp abnormalities in asymptomatic head-injured infants. Pediatr Emerg Care 2001; 17:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/31\">",
"      Shane SA, Fuchs SM. Skull fractures in infants and predictors of associated intracranial injury. Pediatr Emerg Care 1997; 13:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/32\">",
"      Erlichman DB, Blumfield E, Rajpathak S, Weiss A. Association between linear skull fractures and intracranial hemorrhage in children with minor head trauma. Pediatr Radiol 2010; 40:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/33\">",
"      Yamamoto LG, Bart RD Jr. Transient blindness following mild head trauma. Criteria for a benign outcome. Clin Pediatr (Phila) 1988; 27:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/34\">",
"      Ferrera PC, Reicho PR. Acute confusional migraine and trauma-triggered migraine. Am J Emerg Med 1996; 14:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/35\">",
"      Shaabat A. Confusional migraine in childhood. Pediatr Neurol 1996; 15:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/36\">",
"      Kieslich M, Fiedler A, Heller C, et al. Minor head injury as cause and co-factor in the aetiology of stroke in childhood: a report of eight cases. J Neurol Neurosurg Psychiatry 2002; 73:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/37\">",
"      Shaffer L, Rich PM, Pohl KR, Ganesan V. Can mild head injury cause ischaemic stroke? Arch Dis Child 2003; 88:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/38\">",
"      Chung S, Schamban N, Wypij D, et al. Skull radiograph interpretation of children younger than two years: how good are pediatric emergency physicians? Ann Emerg Med 2004; 43:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/39\">",
"      Blackwell CD, Gorelick M, Holmes JF, et al. Pediatric head trauma: changes in use of computed tomography in emergency departments in the United States over time. Ann Emerg Med 2007; 49:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/40\">",
"      Mannix R, Bourgeois FT, Schutzman SA, et al. Neuroimaging for pediatric head trauma: do patient and hospital characteristics influence who gets imaged? Acad Emerg Med 2010; 17:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/41\">",
"      Brenner D, Elliston C, Hall E, Berdon W. Estimated risks of radiation-induced fatal cancer from pediatric CT. AJR Am J Roentgenol 2001; 176:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/42\">",
"      Karlsson P, Holmberg E, Lundell M, et al. Intracranial tumors after exposure to ionizing radiation during infancy: a pooled analysis of two Swedish cohorts of 28,008 infants with skin hemangioma. Radiat Res 1998; 150:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/43\">",
"      Ron E, Lubin JH, Shore RE, et al. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res 1995; 141:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/44\">",
"      Klig JE. Issues of computerized tomography scans in children and implications for emergency care. Curr Opin Pediatr 2006; 18:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/45\">",
"      Brody AS, Frush DP, Huda W, et al. Radiation risk to children from computed tomography. Pediatrics 2007; 120:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/46\">",
"      Brenner DJ, Hall EJ. Computed tomography--an increasing source of radiation exposure. N Engl J Med 2007; 357:2277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/47\">",
"      Dunning J, Batchelor J, Stratford-Smith P, et al. A meta-analysis of variables that predict significant intracranial injury in minor head trauma. Arch Dis Child 2004; 89:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/48\">",
"      Oman JA, Cooper RJ, Holmes JF, et al. Performance of a decision rule to predict need for computed tomography among children with blunt head trauma. Pediatrics 2006; 117:e238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/49\">",
"      Maguire JL, Boutis K, Uleryk EM, et al. Should a head-injured child receive a head CT scan? A systematic review of clinical prediction rules. Pediatrics 2009; 124:e145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/50\">",
"      Palchak MJ, Holmes JF, Vance CW, et al. Does an isolated history of loss of consciousness or amnesia predict brain injuries in children after blunt head trauma? Pediatrics 2004; 113:e507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/51\">",
"      Atabaki SM, Stiell IG, Bazarian JJ, et al. A clinical decision rule for cranial computed tomography in minor pediatric head trauma. Arch Pediatr Adolesc Med 2008; 162:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/52\">",
"      Pickering A, Harnan S, Fitzgerald P, et al. Clinical decision rules for children with minor head injury: a systematic review. Arch Dis Child 2011; 96:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/53\">",
"      Bressan S, Romanato S, Mion T, et al. Implementation of adapted PECARN decision rule for children with minor head injury in the pediatric emergency department. Acad Emerg Med 2012; 19:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/54\">",
"      Tang PH, Lim CC. Imaging of accidental paediatric head trauma. Pediatr Radiol 2009; 39:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/55\">",
"      Nigrovic LE, Lee LK, Hoyle J, et al. Prevalence of clinically important traumatic brain injuries in children with minor blunt head trauma and isolated severe injury mechanisms. Arch Pediatr Adolesc Med 2012; 166:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/56\">",
"      Nigrovic LE, Schunk JE, Foerster A, et al. The effect of observation on cranial computed tomography utilization for children after blunt head trauma. Pediatrics 2011; 127:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/57\">",
"      Homer CJ, Kleinman L. Technical report: minor head injury in children. Pediatrics 1999; 104:e78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/58\">",
"      Hamilton M, Mrazik M, Johnson DW. Incidence of delayed intracranial hemorrhage in children after uncomplicated minor head injuries. Pediatrics 2010; 126:e33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/59\">",
"      Holmes JF, Borgialli DA, Nadel FM, et al. Do children with blunt head trauma and normal cranial computed tomography scan results require hospitalization for neurologic observation? Ann Emerg Med 2011; 58:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/60\">",
"      Dias MS, Carnevale F, Li V. Immediate posttraumatic seizures: is routine hospitalization necessary? Pediatr Neurosurg 1999; 30:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/61\">",
"      McCrory P. Does second impact syndrome exist? Clin J Sport Med 2001; 11:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/62\">",
"      Kirkwood MW, Yeates KO, Wilson PE. Pediatric sport-related concussion: a review of the clinical management of an oft-neglected population. Pediatrics 2006; 117:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/63\">",
"      Carroll LJ, Cassidy JD, Peloso PM, et al. Prognosis for mild traumatic brain injury: results of the WHO Collaborating Centre Task Force on Mild Traumatic Brain Injury. J Rehabil Med 2004; :84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/64\">",
"      Casey R, Ludwig S, McCormick MC. Morbidity following minor head trauma in children. Pediatrics 1986; 78:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/65\">",
"      Bijur PE, Haslum M, Golding J. Cognitive and behavioral sequelae of mild head injury in children. Pediatrics 1990; 86:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/66\">",
"      Wrightson P, McGinn V, Gronwall D. Mild head injury in preschool children: evidence that it can be associated with a persisting cognitive defect. J Neurol Neurosurg Psychiatry 1995; 59:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/67\">",
"      Ewing-Cobbs L, Fletcher JM, Levin HS, et al. Longitudinal neuropsychological outcome in infants and preschoolers with traumatic brain injury. J Int Neuropsychol Soc 1997; 3:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/68\">",
"      Hawley CA, Ward AB, Magnay AR, Long J. Outcomes following childhood head injury: a population study. J Neurol Neurosurg Psychiatry 2004; 75:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/69\">",
"      Anderson V, Catroppa C, Morse S, et al. Outcome from mild head injury in young children: a prospective study. J Clin Exp Neuropsychol 2001; 23:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/70\">",
"      McKinlay A, Dalrymple-Alford JC, Horwood LJ, Fergusson DM. Long term psychosocial outcomes after mild head injury in early childhood. J Neurol Neurosurg Psychiatry 2002; 73:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/71\">",
"      Anderson V, Catroppa C, Morse S, et al. Functional plasticity or vulnerability after early brain injury? Pediatrics 2005; 116:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/38/12906/abstract/72\">",
"      Teasdale TW, Engberg AW. Cognitive dysfunction in young men following head injury in childhood and adolescence: a population study. J Neurol Neurosurg Psychiatry 2003; 74:933.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6559 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-7B7E1375F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_38_12906=[""].join("\n");
var outline_f12_38_12906=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H43\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Minor head trauma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Children younger than two years of age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Children two years of age and older",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Mild traumatic brain injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Concussion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MECHANISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      INCIDENCE OF INTRACRANIAL INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Common clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Skull fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Other clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      INDICATIONS FOR NEUROIMAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Predictors of intracranial injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Children younger than two years",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Perform imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Observe or perform imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Do not perform imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Children two years of age and older",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Perform neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Observe or perform neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Do not perform neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Neurosurgical consultation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Disposition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Home management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Office or emergency department",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Discharge instructions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Hospital admission",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Post-traumatic seizure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Return to play",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      SEQUELAE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Second impact syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Postconcussion syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Indications for neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      - Infants and children younger than two years of age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      - Children two years of age and older",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      Disposition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6559\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6559|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/17/32031\" title=\"picture 1\">",
"      Traumatic hemotympanum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6559|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/58/2989\" title=\"table 1\">",
"      Glasgow and pediatric coma scales",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/5/15452\" title=\"table 2\">",
"      Low risk ciTBI child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23178?source=related_link\">",
"      Approach to neuroimaging in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32985?source=related_link\">",
"      Child abuse: Epidemiology, mechanisms, and types of abusive head trauma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40249?source=related_link\">",
"      Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20602?source=related_link\">",
"      Child abuse: Eye findings in children with abusive head trauma (AHT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7367?source=related_link\">",
"      Classification of trauma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29626?source=related_link\">",
"      Concussion and mild traumatic brain injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4250?source=related_link\">",
"      Initial approach to severe traumatic brain injury in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/47/8947?source=related_link\">",
"      Patient information: Closed head injury (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/12/22722?source=related_link\">",
"      Patient information: Concussion (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/44/14020?source=related_link\">",
"      Patient information: Head injury in children and adolescents (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/45/40658?source=related_link\">",
"      Patient information: Head injury in children and adolescents (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/24/34178?source=related_link\">",
"      Patient information: Skull and facial fractures (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33929?source=related_link\">",
"      Postconcussion syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=related_link\">",
"      Procedural sedation in children outside of the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13704?source=related_link\">",
"      Skull fractures in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_38_12907="Antimicrobial prophylaxis for ophthalmic surgery";
var content_f12_38_12907=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F87203&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F87203&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antimicrobial prophylaxis for ophthalmic surgery",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Common pathogens",
"       </td>",
"       <td class=\"subtitle1\">",
"        Antimicrobials",
"       </td>",
"       <td class=\"subtitle1\">",
"        Usual adult dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        S. epidermidis, S. aureus, streptococci, enteric gram-negative bacilli, Pseudomonas spp",
"       </td>",
"       <td>",
"        Gentamicin, tobramycin, ciprofloxacin, gatifloxacin, levofloxacin, moxifloxacin, ofloxacin or neomycin-gramicidin-polymyxin B",
"       </td>",
"       <td>",
"        Multiple drops topically over 2 to 24 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"        cefazolin",
"       </td>",
"       <td>",
"        100 mg subconjunctivally",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     <p>",
"      &nbsp;",
"     </p>",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with special permission from: Treatment Guidelines from The Medical Letter, October 2012; Vol. 10 (122):73.",
"     <a href=\"file://www.medicalletter.org\" style=\"FONT-STYLE: italic\" target=\"_blank\">",
"      www.medicalletter.org",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_38_12907=[""].join("\n");
var outline_f12_38_12907=null;
var title_f12_38_12908="Efficacy peg IFN alfa 2a";
var content_f12_38_12908=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F57374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F57374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Efficacy of pegylated interferon alfa-2a monotherapy sustained virologic response by stage of fibrosis and hepatitis C virus genotype*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Fibrosis score",
"       </td>",
"       <td class=\"subtitle1\">",
"        PEG (40kDa) IFN &alpha;-2a 180&micro;g, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        IFN &alpha;-2a",
"3 MIU or IFN &alpha;-2a 6/3 MIU, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        0, 1 (n = 810)&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        All",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Genotype 1",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Genotype non-1",
"       </td>",
"       <td>",
"        54",
"       </td>",
"       <td>",
"        34",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        3 or 4 (n = 319)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        All",
"       </td>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Genotype 1",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Genotype non-1",
"       </td>",
"       <td>",
"        44",
"       </td>",
"       <td>",
"        11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        4 only (n = 200)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        All",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Genotype 1",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Genotype non-1",
"       </td>",
"       <td>",
"        49",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    This analysis includes patients across three large trials.",
"    <div class=\"footnotes\">",
"     * Excludes one patient in an IFN &alpha;-2a arm without a fibrosis score.",
"     <br>",
"      &bull; Includes patients without a genotype determination.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from Pockros, PJ, et al. Hepatology 2000; 32:442A; all differences were statistically significant.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_38_12908=[""].join("\n");
var outline_f12_38_12908=null;
var title_f12_38_12909="Gr3 chemo tox elderly pts";
var content_f12_38_12909=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F66108&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F66108&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Grade 3 or worse chemotherapy toxicity in fit older patients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"3\">",
"        Toxicity in percent",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"8\">",
"        Regimen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        FOLFOX",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Irinotecan/FU/LV",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        FU/LV",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        FU/LV",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        &ge;70 years",
"       </td>",
"       <td class=\"subtitle3\">",
"        &lt;70 years",
"       </td>",
"       <td class=\"subtitle3\">",
"        &ge;70 years",
"       </td>",
"       <td class=\"subtitle3\">",
"        &lt;70 years",
"       </td>",
"       <td class=\"subtitle3\">",
"        &ge;70 years",
"       </td>",
"       <td class=\"subtitle3\">",
"        &lt;70 years",
"       </td>",
"       <td class=\"subtitle3\">",
"        &ge;70 years",
"       </td>",
"       <td class=\"subtitle3\">",
"        &lt;70 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leukopenia",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        8*",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neutropenia",
"       </td>",
"       <td>",
"        49*",
"       </td>",
"       <td>",
"        43",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infection",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thrombocytopenia",
"       </td>",
"       <td>",
"        5*",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stomatitis",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diarrhea",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        23",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nausea/vomiting",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        11/10",
"       </td>",
"       <td>",
"        11/10",
"       </td>",
"       <td>",
"        4/3",
"       </td>",
"       <td>",
"        6/5",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fatigue",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neurotoxicity",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     -: not reported; FU: fluorouracil; LV: leucovorin.",
"     <br>",
"      * p value &ge;70 versus &lt;70 statistically significant.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     1. Goldberg, R, et al. J Clin Oncol 2006; 24:4085.",
"     <br>",
"      2. Folprecht, J, et al. J Clin Oncol 2008; 26:1443.",
"      <br>",
"       3. Sargent, D, et al. N Engl J Med 2001; 345:1091.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_38_12909=[""].join("\n");
var outline_f12_38_12909=null;
var title_f12_38_12910="Manifestations Turner syndrome";
var content_f12_38_12910=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F60006&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F60006&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Approximate incidence of major clinical abnormalities in Turner's syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1\">",
"            Physical abnormalities",
"           </td>",
"           <td class=\"subtitle1\">",
"            Incidence, percent",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"            Skeletal growth disturbances",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Short stature",
"           </td>",
"           <td>",
"            100",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Short neck",
"           </td>",
"           <td>",
"            40",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Abnormal upper to low segment ratio",
"           </td>",
"           <td>",
"            97",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cubitus valgus",
"           </td>",
"           <td>",
"            47",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Short metacarpals",
"           </td>",
"           <td>",
"            37",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Madelung deformity",
"           </td>",
"           <td>",
"            7.5",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Scoliosis",
"           </td>",
"           <td>",
"            12.5",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Genu valgum",
"           </td>",
"           <td>",
"            35",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Characteristic facies with micrognathia",
"           </td>",
"           <td>",
"            60",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            High arched palate",
"           </td>",
"           <td>",
"            36",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"            Physical abnormalities",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Growth failure",
"           </td>",
"           <td>",
"            90",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Gonadal dysgenesis",
"           </td>",
"           <td>",
"            90",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Inverted, widely spaced nipples",
"           </td>",
"           <td>",
"            74",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Webbed neck",
"           </td>",
"           <td>",
"            74",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Nail dysplasia",
"           </td>",
"           <td>",
"            74",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Defective dental development",
"           </td>",
"           <td>",
"            74",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Renal dysgenesis",
"           </td>",
"           <td>",
"            53",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cardiac malformation",
"           </td>",
"           <td>",
"            53",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Skeletal dysgenesis",
"           </td>",
"           <td>",
"            53",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Otitis media",
"           </td>",
"           <td>",
"            53",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Edema of hands and feet",
"           </td>",
"           <td>",
"            41",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Eye deformities",
"           </td>",
"           <td>",
"            41",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"            Lymphatic obstruction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Webbed neck",
"           </td>",
"           <td>",
"            25",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Low posterior hairline",
"           </td>",
"           <td>",
"            42",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Rotated ears",
"           </td>",
"           <td>",
"            Common",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Edema of hands/feet",
"           </td>",
"           <td>",
"            22",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Severe nail dysplasia",
"           </td>",
"           <td>",
"            13",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Characteristic dermatoglyphics",
"           </td>",
"           <td>",
"            35",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1\">",
"            Physical abnormalities",
"           </td>",
"           <td class=\"subtitle1\">",
"            Incidence, percent",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"            Unknown factors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Strabismus",
"           </td>",
"           <td>",
"            17.5",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Ptosis",
"           </td>",
"           <td>",
"            11",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Multiple pigmented nevi",
"           </td>",
"           <td>",
"            26",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"            Physiologic abnormalities",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_left\">",
"            Growth failure",
"           </td>",
"           <td>",
"            100",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_left\">",
"            Otitis media",
"           </td>",
"           <td>",
"            73",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"            Germ cell chromosomal defects",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Gonadal failure",
"           </td>",
"           <td>",
"            90",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Infertility",
"           </td>",
"           <td>",
"            95",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Gonadoblastoma",
"           </td>",
"           <td>",
"            5",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"            Unknown factors - embryogenic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cardiovascular anomalies",
"           </td>",
"           <td>",
"            55",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hypertension",
"           </td>",
"           <td>",
"            7",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Renal and renovascular anomalies",
"           </td>",
"           <td>",
"            39",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"            Unknown factors - metabolic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hashimoto thyroiditis",
"           </td>",
"           <td>",
"            34",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hypothyroidism",
"           </td>",
"           <td>",
"            10",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Alopecia",
"           </td>",
"           <td>",
"            2",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Vitiligo",
"           </td>",
"           <td>",
"            2",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Gastrointestinal disorders",
"           </td>",
"           <td>",
"            2.5",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Carbohydrate intolerance",
"           </td>",
"           <td>",
"            40",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_38_12910=[""].join("\n");
var outline_f12_38_12910=null;
var title_f12_38_12911="Risk strat RINV";
var content_f12_38_12911=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F70623&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F70623&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 529px\">",
"   <div class=\"ttl\">",
"    Emetogenic potential of radiotherapy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 509px; height: 281px; background-image: url(data:image/gif;base64,R0lGODlh/QEZAfcAAP///wISeUNN1tXw/3is/6jW/0J//wAAAAENWkBAQD8/P4CAgL+/vzI5oH6gvwEJPMDAwDxWf2p4fzU8PzFfv4KI5MDE8Zug6fLz/BATNQAEHn9/fwgLEUBciMzMzIiIiFVVVREREaes7FBZ2dnb9+7v9mCKzGlx3jMzMxgiM+7u7niBuDVBlCEma3d3dyg5Vauw0szQ5BMignCh7qqqqomQwFBzqjhQd1Zhps3Q9BAfPyAuRKrAzCAgIERERPDw8GBgYKCgoBAQEODg4Obn+iswMyIiInKAiMfg7hAXImZmZpCQkJmZmdDQ0N3f7bCwsA4QEUdQVVBQULzA2zAwMAsOEWiV3TBFZnBwcEhnmWNwdxwgIlRrf7S471xl2zlARI6U5t3d3ThHVY6gqlVgZlpyiFh+uwAGLQEQcQgJGgELS0VRnQACDxkcULu7u4arzE9aX4CQmSkwhQ0PD7nQ3YWWny1AX53I7ictL0trnwcKD7rS32mW3w0ZM8fh7y8vL3Ch7z5IyBYgLw8VH3V84TpDuzRLbzVmzAEPaR0hXQEOYgABBwwOKAQEDZqgyTY+rRoeH5Klr3eHj2dxrwEMU11pbwEKRK3DzwADFiQyi1J2r0JLT3CPqiU1T2GLzyIrM0Ngjw8PDyUreC40kxQYQgAFJU5kdwAHNAQIER8fHyNEiDlu3V9fX1qBvxIiRDBduz537o+Pj5ywuxozZp+0vwkRIi05RBYdIkNWZl54jz9QXyhMmQwXLx4rPyVHj2WAmZK53XuduwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAD9ARkBAAj/AAEIHEiwoMGDCBMqXMiwocOHECNKnEixosWLGDNq3Mixo8ePIEOKHEmypMmTKFOqXMmypcuXMGPKnEmzps2bOHPq3Mmzp8+fQIMKHUq0qNGjSJMqXcq0qdOnUKNKnUq1qtWrWLNq3cq1q9evYMOKHUu2rNmzaNO2TMC2rdu3cOPKnUu3rt27ePPq3cu3r1+9C4aoHUz0AILDiBMrXsy4sePHkCNLnky5suXLmDNPpnTmQIIgPwiL7nkggOnTqFOrXs26tevXsGPLnk27tu3buGmjUaPhAJAnTRMcGE68uPHjyJMrX868ufPn0KNLn258QcXSubNr3869u/fv4E8j/3rApgeWJkoTMLioAEH49/Dja39gnSJ2+fjz69/P/7WiM4tQsURoRqnHnnv9Jaggd/Rdt+CDEEYooWtqlHKAFEEUZaBF7U3o4YemNWgfiCSWaKJ3aFiCiRBAoBfUhhV1eOKM+ok40X005qjjjqcpckp5gf0EI0Uy8mjkdjZKhOORTDYpIWeegcbTkBMV6eSVsSUZ0ZJYdullfLv19ptOVEpk5ZdohljfjWm26WZ345V33k1lRnTmm1hqCRGXePbpp38ACkigTHVCdOefR+r5EJ+INupoABVemGFMhT506KM5KuoQo5h2imeKK7b4UqUOXeqpiZo2xOmpqbEAAAyo1f8AwAqyuRqDfLayipqPQAq2EqkNmarrh6kytOqVMRQEq2orAFADa64ua5qstMaWq2vJsoBbrtmu1uyzMgBQQp9QfjaoScAyJOywExa70LFYUtvat9C+GuustQJwa3zXzuvso2H6Bhy663GIILsnuqsQvFfKG4AMUwjkBA6uDiRDCQPBGu29U2DsyMMRAzBxACw4Ia6+a4gcQMrSBgADACzgoG8MMchMcwwVC0RrySff+jILOc8a9MXjQiwxDgEk+zK+WMZpnosipbvQughDqHBCDNe2AgzapoZDsv+SDHbL2zn8Mg4yOFGCDPSiZvIaG58mb7JrnJ322iYDrW/SAOD/4AgAa6D2s8wC1TzQviSLG0Deuf58mqvjtl3CuHarLQPdKY/75X8BDhiS1ApRXfWCVyOUNW0sJDsF0qZd7IQMf9NqedvcOYyxDHzj0LasA1Fsr9z4nn177orn2iwMJSBu2uC/y7xsJksLFO64jcMMPUFshz15AMMn+zXM07sZKYYfgZ6Q6KMnWPpBp9eGQ8Qx0Or8yq/m2m/ZTFe+drMfNzuFy32L27RmlTaY6Y9oMkjZvkwGgEmkhnnLmh8AaXW7ySVwbz97GQUBkL2PcY9yfbvb5cCnuDeBikVQy4j5EIK+9PFnfQZpn20IpzcnJA4G87ufdhxmNH0hbYQcTFby/wL4uwEOxIE9rFkACJesfcnKhg+EmQQlyAKMxeB2TMQgzKqor9sBkWggKxzSshU+P/GqB0HCyAoP0kIX1mhNSoLP+/RVrWaJDACOsN/e+uQwNz4JQOayyBoN0kY/ygeGBZGhtVTHOtRArASZWNz+woYnCxrSQwEb00QGWZBCXvI9iCSIImGzta4JTiBT6FrqBEK2T7qSO4iwhJxS2BBOEsSTRiojk0I5kFG+8pc84pygHEIqNwyHBuc7mI7O9jDp9dGRJdwlHLcEzGr6iRIWIt9CKhUGI4TgAMhkoTJzxMxwcdA1ukzUNPdkzXZ+SkUoTEilUAACEIAzmUYqp/SaRf8rO2KsBtOLWAlMqSNeCsSX7kzoiRDRmR5MyiCF8gEKAGDPcLJxnDSKnsX46Sobfit8xzOSQQGAUIWaVEKZHBhC6uSB41i0kxidkT45yM+QflRxEtzRSEuaH9qd1KQICJSUtlmwhFQUnzyaafZWoMAA3HRcOS3oOheVI5/+1JpOw4KvallUhBxVnPnsWzNpii/eJQugOC2iVB10myYKBGksCNkUMhFQDk6CgbeyY1kB0LH6YY8/ArzN8FTjuO5Y1Z1hYhEEJGLLgeAyRxFzYJ6muincZCsT27PcJPBoToHYCndO/ZfJMiEvjLHgsNhSlrco2Sq12mawUTRlOrXmrNn/noaZUR1WuYbK2K5WKabIGsizurRTy8KMezArSAzKSDuN9m1uMEPta56ZGukG9rXnJOxxDcva1TBzdIj4ERq3SpHGCuSxV80SZVVlXBakzIZqi2TrSvhZ0/DvXrTK1n1rw8OQTWxoGGPlDTmGsWXxDl9GmxxZjwZAgm5PVsirAYRLUIPozTUAmz3Zs7an14npFWf2mkSAYVXXgbppN6FarAp9aybgphdJ6zWWcTHmBG3FNWO6vGvhQjsQFkCXBV+kjdlCOLvuvi2wpY3uvyKGAw0iF7Sh/V9hTfNg4R54uBPsaGg3rDn78hWAcPVrXmuruJCiCUoYOpcaWWwnF784/zvFbet2TWS7c3pvdwTxXct+zExZ1aBbWAyZFh08Loc5bAUMdNb86LW9Oe6YmdGil83Cl9smnXEJ5N2IeQGA3je3Js626daJhoy2Ivfvy2dDMr70u+S+MfnJGIPboFFT5WrJC3JbbiqjxxXr6jkwWsYjM1Rda6QTiupzbDaUmz19G1C/qb9ifBjYRjhEPeOXb9riXQlolQmTXXHBTWwwrQvNtCHr619m/ReHC7c3LoIYViIWyMcoTWwdYVNSJdl0p5mtGmfz+9+z8dEieoDpk+h72QCXjb8TzvDUGJuW+U62pRDecNcsvOIJH59KVXJwjOPm4h5/szA955KOh7w2IP8/uUljyQYhzIlSEi8VxVV+mpTT3Joar4nJbw4bm/P8kyNXM6FiHqyZ39znP3chy82TaZ0TXV1GpznSk86ulPZk51RfzdSz7qmgBoi3U3r61KKu8q1zvVFZbXrYD3R2rcf4XW0fVmI1ORSsxz0AZr/7mQEJ9rqLPXRkP3ne9X6l8PYqPX9HKuEHT/hiqyHFwUk8WBu/U81Y/vKYz7zmN895zu9W6ElJwB8UQPrSm/70qCd9KDChgda7/vWwj73sZ0/72tv+9rinvRra9faFUef3wA++8IdP/OIbfzpUgDhTEhALBjj/+dCPvvSd/wdRNOD62M++9rfP/e57//vgD7//+Lvfhgfw/jrjT7/618/+9rv//fCPv/zTLwdGsGjjy5c8GxsggP77//8AGIACOIAEWIAGeIAIOIAtYH4SslMJ+IAQGIESOIEUWIEWeIEYGIGF0AJpwHSRxx78l4EiOIIUuIDnZx8kmIIquIIs2IIueIAN0AaNMEyhp3+EFIIvmIMiaIIN2HtYo4NAGIRCOIQ6KAekcCH453cgSIRMmIA8GCEO2IRSOIVUWIX+VwiiYH/HpoQcgoNWSIVPaDU+aDpfWIZmeIYr+AiJ0IEF9yI22EleiIZDGIYPEoVyeId4mIcHOAptECWghxP6Fod6+IJ0SDpjyD6DmIiKqIeBIAcZ/3B/V/eGtySIi6iChaggdliJmriJVLiBHahVZCKJjkWJnJiBl6g+hxhDpbiKrDiEjyCDNOh0S9iKI3iK/ZGJtJiLukiCRoiEstiFu4iBtvhCqZhIwQiEIwAAGJCBFQAAFvCAGAAAI+CC0TiNZhgIWRhPMDeLx1iCDAiFxShKx3gCAEAC/WcBAFABKZiMy1iBJAAAJ9CMz5iA1ViAIgAAF1CB1XiP+RiAFwAAIiAA7BiEatiBabQWonhepNiNCDiM+4GLtEiO5igA6KiOJDiQGCiP0CiN1MiRBPiPASmFfOiHLBGIDOmNJ3gj41iO55iOzUgC0ZgDAvCSMdl//ygQ+f94jxaAASEpkMqYA8p4AgIABkQgEM/4ku+YAzeZj+gYj+WYlNN4jzgpkECJAdUYjUKJAUTwf/94AUhJAl9JjgORjyNQldXYlWKJk2kpjVZJlQJBBOp4jzkQjfNIgo2YAQLDcQnJaQt5kgXokG90HSs5kRWpkV2Aj4aJjyApAEXpBVIJkP43kP9oARIpAIcJBs0ok0AJBl4AAFvZlBrJj4sJlBWAjvm4jwAJBvjIlYg5EGDpmv5HjstomgJwlqvZf7IpAItZm7OZjiNABBgwAvxYm/DIgp74NAa3lwrQl36pgN8ohoIZjJVJkS7pjLoJkBoJkuhIEBUwnP83kPJ4kwP/IQIaWZEDCZrWqZ3pKAD3KALvmJXSSI5EMJfWaJOtOY8aKQBesJ0CMQLvSZwj0JX7SRABCpm8CaAC8I7duZr/6YKvOIMkFzXKyZzNGYCAmR8QSYFg8I6QWZYCkQNeEIBeAJQAkAPT6KElGqIUqJXT+I5eoJFA6ZXWGaP/2AX/552RqYwz6YzT2X/l6Zs6ip7PSKOQSZqkiaDbaaOsKaP4aZ3UeZrSeKS2eQG0aZtK2pbmCZzCyaDFWYRHqE0gYZIV+oAXih8ZKoH52ZIV0KP+946EoJrPWJFsGoEVwKFwuaPRCAA22ox5qqTiCY842n/gaZ1EOZY/WgHnCY/NOBBK/yqVGJCPXlCUMMmRiyqUS5qf+XkC0TipIxCp5Tilmvqp0uif/dmWKAqW7MmllgqE2KiFyrdm3DimB1imhxSOvZSBQFmUGAAGCFqPOdqObVmPvsqMTuqjxbqJmSmrF1iQ48URYqqsBkir8XGmEViNXmCVGFmNsFmUWRmcOoqgIpimO1qXm3ik0HqBIxlIsAqM5/qXz1mHtnpQGdiYCQqPwuqR/lcB0ViUW3mv9dmuACuEd5mXgjShTLibZSit8EGtEMiP1/qZ6UgILDmAl0mdFSCxExmwGjuEx/lyvYUQTEAcPuAB50OhBiiW/ViUPTmACAuBFbmCCgtK8UpSIridOf8glCgKov4oECTAq26ZohsbtET4oLFITMmmBEwAACHrAyV7gWK5lTe5sgLYsg/4spb4roYYnUK7tVvbi2DKEMASsi7QtBYom/gInJB5Ahyqs6qpjJBZqNYZlgRxAeJpjuLZjxYYs+HBsM1Jjs/ooe04rlW7ni1otVy7gq2qjQpRKS11ACEQBmRbgRKJjo8KmVqKsfJ5nSJQmZe5qBMrALn5sotJr3mLtZg4swcwmP3XngLot9eJt4KbgIYrgOIagYV5rLE5sQ16uA/IrAcJUUTXUkYQuRQokeTYBSBZmcmYjukJkH+KnU46oAMxAi/LnwJhkRWot+DBt5s4nawbgK7/e4/YG7sIOLsqaL4AOKe8K4GBcIQH8FAFEVHIZEzDy0ImW4A9OrrBibEYq7lsmp9VKo3oyKs1Woumi4paq4veC5l5ap1+K549iZQlGpVj2X+H6bYVEKMCAJSr6rfsCJQfzJYDMY8XHI1rap0N/IwNXJrF+Zg5WaJ0ub79F4ONoK4HUShKILIka79O+7mLqbYfGqJS+Y4BCbf3iZubWo2harcEsaoo2YMJjIZUe7IGsbJFSQiuO7uhqZhFmo6TabEv2ZkymbsWsLz9SaD+d8VfLKfHesXT2ZSjmY7DiZWHWwhr2KxEFatCq73fwb1TOMX4O7Gs+5jpmMWEa6zPqJ5x/wmQw/myRTm7HvytGJmqA7GgTFnI1knIJ0yY8Piy7Tmcu6uxjaiFKsZVehy0fOwdfiyA78ih6ngCJAqiITwCcMvEUymXdLmW/xrIE9me/yiTbBynhyy4RBqQpBnH6niTW/l/kdyOGPnLFovMD1yiFpu51HkCyAzKXRqw6dp3YGuwh5vK3bHKAfie17qMWqqaXWDG8FiO1ji6AOCYq4mVgEyACywCpIoBCmrI4+u5erq6AvGo/VeVCiqQ0Qi7oOuMGLnQ76jP60nQmFzGDV3Q28nCQumoL5yPoaysdmyQamfK7Mq14swgqEuB/4mVBUECz2yg1Mmd2ozNLJ2II9CWMv/8haOsWBfxrFs70jAWxQ/4nhK7lcCpoj7ZjhL5zv/sfy9dwItYzzUthCP5tQV7yhvL0/NR0hPY0J4plLA8wpNcy9c5ECfw0qSKr0991v2nho1AcB9dXuAs0gd8i1gtgRuN1nbdgom7hc761jsd18To0wlY13c92CI4Cl8Kvx6h03vs1w8514RNgIH6f8P62BOo1gLS1prG14udkkqiuhabg5Htf5NN2QmIhfbnsSSh2KjM2IGJgtI5seirgqHdf6NN2gXotUmY2pq92py9JZ59u5MqkzRJzWG9mjrJk5I9wqk6l/8MuNWIoneKy3pKuUIJt0f5lO68sUQboSmh2lX/zdoY6ti5+MbV+YyHyaSWycUB2ZiPKbX9d8XaTAgBTL2+qaVzHM/qzLkAgJnUrMHtioVp4HKvmpxUrbFWDWfiHZGwXd6am50Aab1yfJs36tKrWZEnLcItGuFQOgLhWRDkmckSLqu4PXQFHrAHnhvkvIgsWq8vOqNHTKRKCtAIDc0VyY+/CY9SKsD1HZz3zeE8+rmCO9vdSMNU4M0lt9vf3dt70o11+pbqyKcCsadum9R/OtYhLpATHeEDwaueyqmnusgbrpFGjN5Crosdi9kIWeIAe+Ifl+AMKa61a9ssOLB0RydIbuDgbaZuzuTHGudyToJEbuS/GCP3K6ts3mx7//7nii4AZy4kd27ieV6rgL3otn2XOO2Gat6uh24bKU7pMtzNf7h2Id3XSr4onm7bHY3HGvLoax7p05rop76+Nw0EpXwUopd6uI7rocAIGdDrvv7rwB7swj7sxF7sxj7siSCMrr6wsB7rWxvVgk4UzDd91E7tf+ALFJDt2r7t3N7t3v7t4B7u4u7tvpAByl7qm+LsNc2sbfiBHEIBBhDv8j7v9F7v9n7v+J7v+m7vFGDuF7jpKIe6xzfwBF/wBn/wCJ8cPTDgNcge8L7vEB/xEj/x8d7v5w7F9hEBGr/xHN/xHv/xIB/yIj/yJF/yJn/yKJ/yKr/yLG/yhjAIHvgU+v/28BRf8zZP8Rb/78sus9dBAD7/80Af9EI/9ERf9EZ/9Eif9Eq/9Ezf9E7/9FDP9K1gB3pQtA3/7jef9Vqf7zlfuuiuKlEf9mI/9mRf9mZ/9mgP9HnQCb6IeA6/9XAf9wbQ9dm783uLummf93q/93zf937PB6AgCIq76m8v94Zv83T/xODY837f+I7/+JAf+T7vCYagB2xN+Fh/+Jov8Yk/gQBPGzsl+aI/+qRf+k2vCXZAkpie+Zvf+lzv716P8Tdi+rRf+7ZP+oCQB4Jf56IeIzTv+sBP750vgZ8/G6F/+8if/Mqf93wQATAPir1PJL8f/NQ//BFY/AqH98u//dz/3/1OP/VVz902MfPUX/4VD/t1//XG4v3s3/5NzwEcUPtr3/bjr5zTb/6tb/0QiP3qBRAABA4kWNDgAQIJFS5k2NDhQ4gRJU60suPAAQ5WJjq0ceDFRpAhH9440EHkwo4fQXLgcNKlSD6gBAkB0sTgTZw5de4UmIABz50KKBggWtToUaRJlS5l2jQphQwCpE6lWtXq1BYPAmzl2tXrV7BhxXJ9sAAoToQv1a4VOSMJBxsEbKhkW9fu3ZMs8e4l4MmQnh5LhpwlXLigT8MGhTpl3Njx46JQr06mnHXsZcyZt5ZNPDAtX9Ausxy4snAGRoszOFz0KPdAihSvZ5hoHdsE/+2WsV9c7GAxxYyHWZJcTNERdgrarE2S3LH6Y4eSBLKsbj3DIm/jq3cQoP1RN28Cuy/u0Kg3NF5Ndg4kCPKj83uciOEDWAzZ/n37kinvp2pZ838ANzPrvc/OM1AikkxS6DTWgEtoODM62s6iDrojwDbcLjzADDMOSIKAKw7IwiHafkuoI+IUyjBBAlYzAboKXyMAuhtIKu3E1kKM0bsNO2xJod1MMu9AuwDJYyYgnphvSfngqw8/KKNUSj/++PMvQCwv44xAIrt8CLobEzrtRwJIYs2GlMosyUIMMdLwNhlZbIhGhdIkwArxLpqBRdtgpNM4E4bDyIQ0aWTzABPGnP9R0ANuaJFML+viI4JBesBisCUTa/K9J6X0VEoqq6xMqyxLDWvLzgqM1Eu34JLrBUVnPGC73dBsLcFDbciwzRTUNKk5B7mTDUeVgmzxgD2j63NNGelMyMY0KTw00UHdpHPIVe1qxQ49qFjCvUzP2rSzTj81N7+oRN3vSlPbFRA+VbMlsqKLMop1htg4iM3Wj3BtDUWLckO0RF9bpCsh4Yiz04TVUlgtWZOWNWm6i0rLk7yOqCttWkXFi81RbOW1K49ODpBCyXB3Gjexcs91mbFQ1bWKXXdNRTWxeEXWucsOTdiZ2J+DZigmJG1K+aaVDWv5ZaanTFfmq2iuOcubDcv/WTTWdvDZuvE0aiiL2BolgOtZvRb6pQ56DdrOs9v2CzDBjiYo6cKWbvruyJ6Guiqppw6w6sKuPumKEUej9QBdZWSI7fAQJ7htyCOX/KX01mtPbroJsxvvu2PeW6q+/f4PcMIEf2k0kJE9NtiELBqOgxEfXn1y2mu3nSEje6EJ5UwzP2tzzpn2/PPQRc+M9LNMFyk5e91cnbVeH7aCpVhlv/167COftNJLmfzpJg9CuMiHMHICPniXh9+7eOO1HDBVvmj7UHbrFRpOI9voVz17/vv/2RNueQtcmvqeQT7wAQDQ4AA+MN9QPHWIA/QBfUtRH9TY1z6xIA8oygPJDuLS/6EP1apDaltIgqYXQsSN0H8rZKG8SGYy3hHGdwBgwgFQ0MBPQVCCE3yK3j4HOlJhEEAa5AkHNxKi8WztOuRxiHi0NrYlmq2FU6RiaAAhE5oYDSi+o4H4EIiT8zVGh0Y5RB8u4opVqOIAszCAKw7wildE8FMVlNkFhfgVIu7EiFXkYx/96JdKxU1lBTSIEi4CAp2EkTFjLEotUAGLOPYBgrVYxQFQoYpZHEAVc/ThD+14x67kUSd79GMpTcnCyrFngAahGwgu4oKgOFBKjDTAGGFxEViYURWomIUranGAVXDyh3wLIigxI8qckPKUK9nfS2pVF8Y5BEasct4yIwKIkv8dIAjxISRBXMmaA3gAjLKMEi0N4EhIylGNvNwFKg7gCnPRUV2fNGYAkIkWawpLbSRxVF6a6ZJnsiWac4rOeegUq3w2hA+GqNQCMIW0brKMnFCCIDgPUcYzBrOSB9jFRjcpzGFipZj1zOD7cJbPx/HTJfUDKOKg2ZqITNOgYkNoQglgJCRBgCcz5IkieRgleYqKnsa8502UqTNngSSlYktYa5IDHq6xpJlPjQ5znJMQJK4mLmJCzaC4E0VZXeQGKbHCW3xG0IlR5yMWiV1LaDQD8SQhLt/ZKlXHFDCfmSBs5Lkrsqhzq1m16qxtS+XlthhRpU30py8LapWGCsqiHgT/e0ndCFXFSrAQjSghGTIWSzfrJha5CDofCejYrNWat8xgNFcYbZ084rDBMgRGBKMRmChmBgjVygoe0tBFtiorRymqtakdIYP0ZL8NgQgjLj3bQgP5UHEhtm6KXey5GmulkZIULJEtyFEVEpuwxcUEUeyragXVK+iAx6oesatSFcfP9LLmBngCJ74QNbuE0LdBfEIUi0qrqJRYNgWlRZHipFmSP8mGA0m4wg4YzNu/6sk2sqWpmwIsIwYh1Ey+Ne2shHbFor2Hp7Gsbuc6Sbzsatcr3CWIdxNim+m1JLWrNS6ihgVcAtwvtIii7ESWeoPHJaSzyLJIXOo3ZIi9iU5F/16QhVGbEYW0Fkc7sBEBOtTPhMy2WWILWBausBqT7EazL77vQsBk2pakibiycR50DheX3QxnzPLSRMmksM35jDiR1C2xp667rhSrmCwmtZpaJuwicLL5R0nNk2/5+yKxheTH0mFUhRomveE4bKqXRtajCRCwfTU5zU69TmviO9baiAg6sZ0mxUiDsItYYTT3hStrBBbbsYUNwE7dqxXula992cgtyV3V2wIDXfjoGYd9ZuyJ1xdoQduT0IEzNKJAmGMoc/VHJXLQmRXyaG/b1CU7OJi4QQPiLGJOuprjM7Oh9OdRRftU0y5dtVeThLyWGlbVbCp6wWmCR9v3n+aeiP+rCM6XOpsMz3IDgLLH6e70OduC0BY0iz1TbVwfXOPLfJsAGT63df+u3RBHV0hFKu/t0jt5GN94y00Zk0EIAQta/PhAHH4Tn5LcKfCezGPvaHGBuNjlfJHp0Ff1wpPVnJtLyrnOmcLzqFFcxUAHgNCtOWEiFX0hWDe6XQDYrW8pPSc3V8zInd4YqM9M6tqlutW7Xhetv30vMLcUzcUOUaab/ew7l3gd107StufTOLAJa3Rs8DoZ7cZnGzbJ4G+8uNdoJ8vKkVXaRPRpRCmebAWVO0SMVLIk3f2wed87UPs+z7/XM/DWLHAK6HS/4cCpV4pfMuIkhHkFQf4jOnr9Aaz/ACMJ7fZwAH915yOyrW4ZVvQ7DTlQml76o6SdmCjHo8o3KHiYNrokbiKY4p/JzzTJSffA1b4NpjmcEMF5YILiQMblvj1LIXv5gyQ99O8j/f6knqjWLyL2VRLuR5kBFaI9LrM9wBISEnKNtUKw4ps8k0ivD2mcwaoy48udAwi9+TMMsiuI57M/osC/k6O+UOI/PfK/KPs3igEvCVQTjGi8A+yQ3HMNjZk81oA0k1CNgvK+rJEio0M+KlC+DCyMDSSIDvRAEAQiERxBeJE7AASJDohA1yo341sL5+oBhwrCZGu+ntI7D0SKIxQAnxOi1XO5DdsB1ukgLAOaKVwLnKIJ/53CwjzTQhLrwsf4wjDEoDFcQz3UmcJaJTgUMTncMzqsw9MTKv2DLBIcpT1cxFWpwiv8w3AZwoEoQvuzw0P8uURMJkbcxPNoQyB4Q0hMGUkUCEqEPktMwkFbQk5cRbuonDsLxY8bRfrgwkH8wEJ0rEsUw0zEJ1bsxZMwNkGCRYZLgD9QAGM8RmRMRmU0xlDgBR14RmiMRmmcRmqsRmu8RmykRl5ohAzoRm/8RnAMR29MAzbQAHM8R3RMR3VcR3Zsx3Nkg100Kl+cR4lAt5oQRrFLgFhgAH7sR3/8R4Dkxz/IBQcoSIM8SIRMSIVcSIZsSId8SIiMSImcSIjUhXg8iP9Ey0iN3EiO7EiP/EiQDEmRHEmSLEmTPEmUBKcfxEfRk0UFcIACiEmZnEmarEmbvEmczEmd3Eme7Emf/Eme5IKL7C4JKEqjPEqkTEqlXEqmbEqnfEqojEqpnEqqrEqrvMqohIM5+EE/ZMmjcUmYBEqxHEuyLEuzPMubFEp4GQC2bEu3fEu4jEu5nEu6rEu7vEu8zEu93Eu+7Eu/zEs/qINNgCGvHMZANJ+wREvFXEzGbEygVEsC+UvJnEzKrEzLvEzMzMy23ANJgASZs7vCBESmS0zHLE3TPE20hMxU0UzWbE3XfE3YjM1LqIQ5OLbQzMLRRE3d3E3e1EnVxJnYDE7/4RxO4izOtowEOFC4rrxN+puPl+xN6IzO3fxNqzFO67xO7MxOvQxMPHBD5oyu3JRO8RxPxaTOwNFO9ExP9cTOPZAASIi/79QJsCRP+qzPxxzKFltP/dxP/mxNWtBKroxPVjpMMCJN+zxQBJ1J8yyd/mxQB33QvhRMwhTQniBQnDPQBI3ONzgAMchQmVzQ5IFQER1REn1LzuzOmRNQ3/GBcEokDD3QKuDQmBSDA/iEAjCFAygDm7yDA6gCsdzQDvXQAgDRDSpRIz3SB53N2gzGwqQbBboIcUJMIS2AGD2AN9jQGj1NIJ1SIi0iJP1SMNVP5LSc5YRE33GlKC3QKY3R/yoQAzGIURstgxzl0SqwhR59Ayr1URy1hRjFBRqtAjytUhndUiHtUj0KU0RNVOzkzt1hyTNtUSkV0hiV0xzNUjktAzotADnt0CrQ0xyl0gMAhl84AFyYyVs4gGAgVA811FFSVFd91eFsz/fsnlB81DS90DU9gDu4hVvY0Did0x4tAE6Q0U690U+N0TsY1g7FUdbgBFXNUFZNJlidVmp1zf/cyrCDQ1t10Vy9g5j0VU0FVh9V1jw1Vh1FVmWVU1soABp1VhktVPz0jGqdV3q9TAlNuiB0UnBCJDWVVF39VksVV2ElVk89V11V1jv4hB5VWHcN0lWN16CrV4mdWL880f90W775nFKNFc9oRQuK/ViQxUsltc18tFDFeNGNTVnT7Fijgs04+AIkGAAyYI0oiFkeKIKLiIKQ3dnsHFNVqrmMVVmhPU2WPQjXPIItOACdHYAv4AGZPYAjGIAtgAIkOIID0AKezVrrZFQM/EqT5UCUHVqxNcui7S7NRAItuAgyiNm3nNkx4IEDKIIBgFu51Vq7LU5Zhc9I/FoiDNux/dv7XMvMTNsDYFu3tNq4HYAxUNq5Tdy7fVzivFaPi8PwBFzLJcuyzc/MRFu1Ndy2tFoyoNvGrVvILV3hvNcY0kC+nUS/vVzXTUuIrbqjTVqd5YEvoIMBAF2ppVqrxVrT/d3/4LTYe1Tdyn1d4/XN2D0Al4VZJPgCmrVZnGXcyoRb1igCp6XM3pXM7J1MnOUB0R2A7gXevRxZJm1OJ2nd4z3ezJXXaRVdq13aydxev5Rfyvxe8ZVMnwXCpXNO9E3f113fiG3fxLXaqMXZKDiAt3XeA7jdAYACmh2A5mUNxL0Iz21L272I201bmJ1a6qXgA4AC50WCOEhaxl3cIsDZL0DcqD1gHnDgixgDFs5dCR6AOHBhKLhfueTa1D2M1SXF/vXfywVg2RXg6o0D8GWNMZhaET4AMnDLpJWFtG1itqTft1TiOGDip3XgMZBhrEUCcBLdmY2Dxf0Cpj2AOKCDA9iC/wFg4e9l4exNWriFAtzF4brcg+TsgYXj4eIFYj4WYuUV4LpNWjoI3w6+CLkl3BfmARKGAh6gYgtONLn14gWe4quF4A+mZHDSgsXV2QMeAy++YTZ2XBY+YHAag5nNWTqOS64FRVbax4B85YAcSIqcZVquZVu+ZVxmSIsUXFgVXSQQ5PDd3TmWYTLu5LaMYt2V4S1uy6kd5jVOYzOW4Sb+ZLa0X8Vl3E6m5lBW42duZCx+SyRwYGem4zG9szIdCCxIAHVeZ3ZuZ3deZyEoxmWc53n+g1CgZ3xGRnvOZ37eZ37GZ3/+53q+Z4Ge51RI3gd1ZLos5C0w4mC+4JxFApyFAv+chWHWuF2JpuAv4GYLVmCljeJfPgBZyOjCvWS2HGEJ3uRn9uRLjmFStminneAD6GAoiNpUns33LN+7k0UAYAAFWBKfBuqfno+gJuqhho8NQGgHVejsrOlURlI/kITuHF4s5Omiho+rfo+s7oytToyuNoyk5uW9xNno3WKIxugPDmGUHuAZ1mAHjoJCrmDslAWqfeoSjYTBfMVa7WGB+OrC8GvCAOyzEGygIGyeCOvI7MvupQMouGErZmJJvgi6Zds3PgA6SNuodWBv9l277uy3JF/501a+7umj1urS5urT9urUNgzD3gnEXk3FnukGnmlIpmYubktSRmLMPuLN9mz/345qFAXNvd4JFr1VgwDsD2ANfr0JwDakQ1IBnCDs5D4A6Gbu1RYIFAAnWLLunFAB56ZunHht4IxtHpCFNBbmtrTtyaZkKWbL3e7eZPbtVEZd5sycJ4XU6L5uAHABGtjvA/ii49ZvHxAnQwLwghBsBRKf6g7wnMju/tYJwEaBEDBugxDv6oxtB94Cp4VopbVtGiZhuZVpHnjvmSZpuZbvx70EAM3W+m4+NIVw/R4IQ9puBt8JQ3rwGr+JMAiBD1Dw/G5w1vCBBT/w63aDAzCC8RlygrDw8yRvFH9yyuRMz0xRCp2hF88J6YbSH8+J6b6hLTcIFTACJQAAH+duGz+A/zE3cwM6AFgq8PBWar4MZiifc72kbwq1ORfHbzUHcxb9byyPcYFI7jTP8YKYbnBS8r4G9AQ6gOUmcpyooTFXoEZfcjinc0tnTRXH1nP+TivXc0IvCPEJASaAcZzwAPIBAEH/8pwo808fCBU4dTffc4JQgRAwAu/285tgcga9dF63TCnX2zsf0Jy4b0b/81UHpxBQ9Vnvc0ZH9ETnCVZ3dJxgdgOX9pugASTH9Vyv9F7v9u2sgwm4wB0OdpDLlNYmdaMWanWfD10PUW9/97uUXP0ld2Ffd6xW9J04d2NPd3bndnj/d7bMW1qld/O9d3s37YNH7SVp9yIFeIAPzAloVP+CB8+EV+2KZ218R3ek9neHv3TknIOfnXgZGm19V3aL53eD73ex7ng634NKeM9HFHkhJPmM3/eUv3mEV/nEZnkoX2WZFzFW2AChH3qiL3qjH3pWSIWjX/qlT3qmf3qid3qoh3qpn3qmr3qrP3oF4Hief+r83fSf34kgWACyL3uzP3u0T3u1X3u2b3u3f3u4j3u5j3tWvvCut2uXz+nQDnu+73vm/OO7x2Hgvli/L3zDv03AD/zfxWuFO3zHf3yWTHzFv1vQhnzLv3w4lPzJ39nBp2rM/3zQVzrN33yKZXy9Dn3UT/2jOYAJaH3Xf33Yj33Zn33ar33bv33cz33d333/3u993//93Nd01R9+4p8PCDh+5E9+5V9+5m9+539+6I9+6Z9+6q9+679+7M9+6hfu4u9+7/9+8A9/8R9/8i9/8z9/9E9/9V9/9m9/939/+I9/+Z9/+q9/+79//M9//d9//gcIAAIHEixo8CDChAoXMmzo8CHEiBInUqxo8SLGjBo3cuzo8SPIkCJHkixp8iTKlCpXsmzp8iXMmDJn0qxp8ybOnDp38uzp8yfQoEKHEi1q9CjSpEqXMm3q9CnUqFKnUq1q9SrWrFq3cu3q9SvYsGLHki1r9izatGrXsm3r9i3cuHLn0q1r9y7evHr38u3r9y9TEAc8LPRg5AAIiR4O/6B4qOJACLguDnyAaRixTSYHXJD8cEBJUs8HRh9QEdEzZ440MF8UTOMhaoEoBh8UTFihD9qKGQOYfbtg7MeRvQom7UOF8IOTK7/M/Rv2ZgDJHbpeqCJE44e+EYYojdA20tgUxdus7pB8QvAKZ5venT1hcMhfqwtmjnA5TPYS0T80D//Aaxp1155Bi4F2FHqzFfdBbiiYxsRhiC1GmgpMdMeaaN1xBuFoiU3mQ3eJLSZibqMRONls0alQohE0iMbbi5V9GOKEJtr2YosAqCeQhR3qSFqAAEwGQggu4PjaZd01Bt5ko31QY2mQ5RYCYR6U6EMYq6GwJZQyMjYaZ90RFv+CETtVl9trIUTmQYqDLaclgWyS5oEKxQEo5wFY9obYnVeGQRCeWNoZpJbd+QBAl1BeF1mdo7Uo3JQevOhgiZQRBOJAKIIpHYuv2ablbA7a6QKeuhkxnFEv8jabG24cUKYSBzCxWGOxMhEbrQCgtliZu/JmK35ijgjAqc8JhB+rrqlwaqOvxXZYGMEOJt6Onh26Y66xDUhQk9EJZC2xg+V6Y3RoxheZZ4kxq5kSq4323mKRIXuAG5O5oJl9ONlpKQBq7slEppthR+C/A9U3ELOuNtYmDet+RlDCvG070GqJxWpfvLp6669rYbyaXLo/vjbZgQUZUeaxliYL4LIhNOr/wWqH5lbZtrMBTJBgBA+VoLi8LafqZrHFpmXIqAHtwrwejJirQfi5VjOA9JE2Gg1JUzsYDZUuqZvGnGnZr3cBM5c1aQ7KN+5g1dl7LgAVQ8lYxQKFsa8KTt/5Kog6lxf1w/1Gptm7dZNWMo9lXxd2ro+Vtt3b8PKm+OEEx43a3FOrIJ6/F1IoX9zVXQbZcyeLLTLUNHyKmbQPGi5Qzgh6K1vPjS3H9LcPZ7uZwl3TLqTKPatLZdOULZs2y8wKBrBnhFvdt23duYH2b7eHGXbKzDmfq5oq5E4uZ+Y+nFzcp/4pUNw/0lzacsMTVhzh+hYvq98E2byczQfZfLBAES9s/2oI45vscu4mRj7MzOxgA0qeQDgGP4GADzPH41bfBIKp6qlPWcbDGuos1R3/FYxYqCoK0FTgm1zhh0NOEqGJetS3Js1mQxGiTNKGZSUKBexCAFvRu5CkJI3NKWkoLA25vrS156jwQALkHXNEE6q2vYs3TBpNCCrzwwaSiDQgKJ8HlDSgydhwgFzLSXVW07/MDQ6JYVCT/zQHmkZRLVB/2g6iKpWYgbgRbJKDzGhAk0XGDGiK/mIjZKiIKCXZSU8D8UyAuDiaG5YIBZ7CoIcsJRoXqFEgBnpLbm6WEfzshZMUyxNgEFK+llwnO570yI7S0qbUaOSUeHElmkJ5kFG2REEznHHlRhAoy13yspe+/CUwgynMYRKzmMY8JjKTqcxlMrOZznwmNKMpzWlSs5rWvCY2s6nNbXKzm978JjjDecyAAAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Feyer, P. Acta Oncol 2004; 43 Suppl 15:5, and Feyer, P, et al. Support Cancer Care 2005; 13:122.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_38_12911=[""].join("\n");
var outline_f12_38_12911=null;
